

# Evolutionary rescue by aneuploidy in tumors exposed to anti-cancer drugs

Remus Stana<sup>1</sup>, Uri Ben-David<sup>2</sup>, Daniel B. Weissman<sup>3</sup>, and Yoav Ram<sup>1,\*</sup>

<sup>1</sup>School of Zoology, Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel

<sup>2</sup>Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

<sup>3</sup>Department of Physics, Emory University, Atlanta, GA, USA

\*Corresponding author: Yoav Ram (e-mail: yoavram@tauex.tau.ac.il)

March 11, 2025

## Abstract

Evolutionary rescue occurs when a population, facing a sudden environmental change that would otherwise lead to extinction, adapts through beneficial mutations, allowing it to recover and persist. A prime example of evolutionary rescue is the ability of cancer to survive exposure to treatment. One evolutionary mechanism by which a population of cancer cells can adapt to chemotherapy is aneuploidy. Aneuploid cancer cells can be more fit in an environment altered by anti-cancer drugs, because aneuploidy disrupts the pathways usually targeted by the drugs. Indeed, aneuploidy is highly prevalent in tumors, and some anti-cancer drugs fight cancer by increasing chromosomal instability. Here, we model the impact of aneuploidy on the fate of a population of cancer cells. We use multi-type branching processes to approximate the probability that a tumor survives drug treatment as a function of the initial tumor size, the rates at which aneuploidy and other beneficial mutations occur, and the growth rates of the drug-sensitive and drug-resistant cells. We also investigate the effect of the pre-existent aneuploid cells on the probability of evolutionary rescue. Finally, we estimate the tumor's mean recurrence time to revert to its initial size following treatment and evolutionary rescue. We propose that aneuploidy can play an essential role in the relapse of smaller secondary tumors.

Keywords: aneuploidy, evolutionary model, adaptive evolution, cancer, drug resistance, chromosome instability

## 28 Introduction

**Aneuploidy in cancer.** Each year, approximately 10 million people die from cancer globally (Kocarnik et al., 2022). Understanding the factors that contribute to the failure of interventions is of great importance. One suggested factor is aneuploidy, in which cells are characterized by an imbalanced karyotype and alterations in the number of chromosomes (Schukken and Foijer, 2018). Aneuploidy is caused by chromosomal instability and missegregation of chromosomes during mitosis. Importantly, changes in the number of chromosomes and chromosome arm copies allow cancer cells to survive under stressful conditions such as drug therapy (Ippolito et al., 2021, Lukow et al., 2021, Rutledge et al., 2016). Indeed, cancer cells are often aneuploid, and aneuploidy is associated with poor patient outcomes (Ben-David and Amon, 2020, Smith and Sheltzer, 2018).

Ippolito et al. (2021) induced aneuploidy in cancer cell lines by exposing them to reversine, a small-molecule inhibitor of the mitotic kinase Mps1, and then to anti-cancer drugs such as vemurafenib. Reversine-treated cells had a higher proliferation rate following drug exposure than sensitive cancer cells, due to selection of specific beneficial karyotypes. Similarly, Lukow et al. (2021) induced aneuploidy in cancer cells and observed that such cells have an advantage compared to sensitive cells during drug treatment despite having lower fitness before the onset of treatment. One proposed mechanism through which aneuploidy can confer resistance to anti-cancer drugs is by extending the length of the cell cycle, which prevents the drugs from damaging DNA and microtubules (Replogle et al., 2020). Other mechanisms are the selection for specific karyotypes that lead to reduced drug metabolism (Ippolito et al., 2021) and elevated levels of DNA damage repair due to higher basal levels of DNA damage (Zerbib et al., 2023).

An essential aspect of aneuploidy is that the rate with which cells become aneuploid, that is, the rate of chromosome missegregation, is several orders of magnitude higher than mutation rate (Bakker et al., 2023). A cell exposed to stress, such as chemotherapeutic drugs, can acquire aneuploidy faster than a mutation. Some proposed anti-cancer drugs elevate the missegregation rate to fight cancer cells (Lee et al., 2016), as an extremely high chromosome missegregation rate is incompatible with cell survival and proliferation.

**Evolutionary rescue.** Populations adapted to a specific environment are vulnerable to environmental changes, which might cause the population's extinction. Examples of such environmental changes include climate change, invasive species, and the onset of drug therapies. Adaptation is a race against time as the population size decreases in the new environment (Tanaka and Wahl, 2022). *Evolutionary rescue* is the process by which the population acquires an adaptation that increases fitness in the new environment such that extinction is averted. There are three potential ways for a population to survive environmental change (Alexander et al., 2014, Bell, 2017): migration to a new habitat similar to the one before the onset of environmental change (Cobbold and Stana, 2020, Harsch et al., 2014, Zhou, 2022); adaptation by phenotypic plasticity without genetic modification (Carja and Plotkin, 2017, 2019, Gunnarsson et al., 2020, Levien et al., 2021); and adaptation through genetic modifications, like mutation (Gomulkiewicz and Holt, 1995, Orr and Unckless, 2014, Uecker and Hermisson, 2011, 2016, Uecker et al., 2014). Here, we focus on the latter.

There has been extensive theoretical analysis of evolutionary rescue. Orr and Unckless (2008, 2014) thoroughly investigated the simplest case in which there is a specific single mutation or low-frequency variant that is sufficient to rescue the population. Martin et al. (2013) extended these results to consider the effects of a range of rescue genotypes that can vary in both growth rate and variance in offspring number. Importantly for the present work, they also argued that two-step processes involving a "transient" intermediate genotype with growth rate close to zero may be an important form of rescue; however, they only calculated that the rate of such rescues should scale with the total number of such transient genotypes produced. Osmond et al. (2020) derived approximate expressions for the rate of

these two-step rescues in limiting cases and found that for some parameter values two-step rescue is more likely than rescue by a single step.

Resistance to cancer therapy is a natural application of evolutionary rescue theory (Alexander et al., 2014). Iwasa et al. (2003) used multi-type branching process theory to approximate the probability that a population under strong selective pressure can survive extinction, focusing on the case in which the cancer must get two mutations to be rescued, with the single-mutant still dying rapidly. Iwasa et al. (2004) used a similar approach to find simple approximate expressions for the probability that a single lineage would evolve to survive via a wide range of possible mutational pathways. These results are essentially the same as those described later in the general context by Osmond et al. (2020) for the probability of evolutionary rescue by multiple mutations, which we mentioned in the previous paragraph. A similar set of models describe adaptation to new environments (e.g., a pathogen evolving to cross a species barrier) and fitness valley crossing (Antia et al., 2003, Weissman et al., 2009). Gunnarsson et al. (2020) analyzed a model where a tumor consisting of two populations of cancer cells, one drug-resistant and the other drug-sensitive, can evade extinction by cells switching between the two phenotypes through epigenetic mutations. They found that even when drug-resistant cells are barely viable, the epimutations guarantee evolutionary rescue.

Here, we study evolutionary rescue after a sudden environmental change caused by initiating anti-cancer drug treatment. We consider a range of effects of aneuploidy, from tolerance to (partial) resistance to the drug (Brauner et al., 2016); note that we use tolerant to refer to aneuploids which have negative growth rates, which is different from other references in the literature such as Berman and Krysan (2020). We estimate the effect of aneuploidy on the tumor’s evolutionary rescue probability. When aneuploidy provides drug resistance, it can directly rescue the tumor. However, when aneuploidy provides tolerance to the drug, it may act as an evolutionary “stepping stone” or “springboard” (Martin et al., 2013, Osmond et al., 2020, Yona et al., 2015), delaying extinction, and thereby allowing the tumor more time to acquire a resistance mutation on top of the aneuploid background. As mentioned above, evidence suggests that aneuploidy may be a common strategy for tumor adaptation to drug therapy. Still, it is unknown how often aneuploidy provides tolerance and acts as a stepping stone. We also estimate the mean time until a tumor cell population reaches its pre-treatment size following drug therapy. Given that aneuploidy is present in many tumors before the onset of therapy (Ben-David and Amon, 2020, Lukow et al., 2021), we also consider the effect of pre-treatment standing genetic variation on the evolutionary dynamics. Additionally, we are interested in the timescale of evolutionary rescue and the impact that aneuploidy has on the time necessary for the tumor to overcome drug therapy.

We will address these questions essentially by combining known results from the evolutionary rescue literature, and considering the quantities and parameter values that are relevant for cancer. Because these results are scattered across multiple papers, and because they all follow from simple branching process approximations, we re-derive all results here for our model. While our focus is on the application of evolutionary rescue theory to the evolution of drug resistance in cancer, our model is a general one, and in the general evolutionary rescue context, this work can be seen as a characterization of the circumstances in which two-step processes contribute to rescue even when single-step rescue mutations are available, as in Iwasa et al. (2003, 2004) and Osmond et al. (2020).

## Methods

**Evolutionary model.** We follow the number of cancer cells with one of three different genotypes at time  $t$ : sensitive,  $s_t$ ; tolerant/resistant aneuploid,  $a_t$ ; and resistant mutant,  $m_t$ . These cells divide and die with rates  $\lambda_k$  and  $\mu_k$  (for  $k = s, a, m$ ). The division and death rate difference is  $r_k = \lambda_k - \mu_k$ . We assume the population of cells is under a strong stress, such as drug therapy, and therefore  $r_s < 0$ , whereas the mutant is resistant to the stress,  $r_m > 0$ . We consider a range of possible values for  $r_a$ ,

finding three distinct scenarios: in the first, aneuploid cells are partially resistant,  $r_m > r_a > 0$ ; in the  
 122 second, aneuploid cells are tolerant,  $0 > r_a > r_s$  (tolerant cells are able to survive the effects of the  
 drug for an extended period of time compared to susceptible cells while resistant cells require a higher  
 124 drug concentration to be affected, see Brauner et al., 2016, for a detailed explanation of the distinction  
 between susceptible, resistant, and tolerant); in the third, aneuploid cells are non-growing, stationary,  
 126 or growing or dying slowly, that is, either slightly tolerant or slightly resistant, such that  $r_a \approx 0$ , in a  
 sense that we will make precise below.

128 We assume that both chromosomal missegregation and mutations occur during the process  
 of mitosis. Sensitive cells may divide and then missegregate to become aneuploids at rate  $u\lambda_s$ .  
 130 Both aneuploid and sensitive cells may divide and mutate to become mutants at rates  $v\lambda_a$  and  $v\lambda_s$ ,  
 respectively. To model standing genetic variation, we assume that before the onset of therapy, sensitive  
 132 cells become aneuploid with rate  $\tilde{u}\lambda_s$  (which may differ from  $u\lambda_s$ ) and that aneuploidy confers a fitness  
 cost  $c$  in the drug-free environment, that is, we assume that aneuploid cells have an increased death rate  
 134 compared to sensitive cells in a drug-free environment. We assume that  $c$  is not too small (Table 1), so  
 that standing variation is generated by a balance between the generation of aneuploids and selection  
 136 against them, without the effect of genetic drift.

See Figure 1 for a schematic representation of the model and Figure 2 for sample trajectories of  
 138 the different genotypes.

**Stochastic simulations.** Simulations are performed using the *Gillespie stochastic simulation algo-*  
 140 *rithm* (Gillespie, 1976, 1977) implemented in Python (Van Rossum and Others, 2007). The simulation  
 monitors the number of cells of each type: sensitive, aneuploid, and mutant. Initially, the population  
 142 starts with only sensitive cells,  $s_0 = N$ , and the other genotypes are initially absent.

The cell population at time  $t$  is represented by the triplet  $(s_t, a_t, m_t)$ . The following describes the  
 144 events that may occur (right column), the rates at which they occur (middle column), and the effect  
 these events have on the population (left column, see Figure 1):

	$(+1, 0, 0) :$	$\lambda_s s_t (1 - u - v)$	(birth of sensitive cell) ,
	$(-1, 0, 0) :$	$\mu_s s_t$	(death of sensitive cell) ,
	$(0, +1, 0) :$	$u\lambda_s s_t$	(sensitive cell divides and becomes aneuploid) ,
	$(0, 0, +1) :$	$v\lambda_s s_t$	(sensitive cell divides and becomes mutant) ,
146	$(0, +1, 0) :$	$\lambda_a a_t (1 - v)$	(birth of aneuploid cell) ,
	$(0, -1, 0) :$	$\mu_a a_t$	(death of aneuploid cell) ,
	$(0, 0, +1) :$	$v\lambda_a a_t$	(aneuploid cell divides and becomes mutant) ,
	$(0, 0, +1) :$	$\lambda_m m_t$	(birth of mutant cell) ,
	$(0, 0, -1) :$	$\mu_m m_t$	(death of mutant cell) .

For the remainder of this paper, we assume that the division rates of sensitive and aneuploid cells  
 148 can be written as  $\lambda_s s_t (1 - u - v) \approx \lambda_s s_t$  and  $\lambda_a a_t (1 - v) \approx \lambda_a a_t$  because  $u, v \ll 1$  (Table 1). Each  
 iteration of the simulation loop starts by computing the rates  $v_k$  of each event  $k$ . We then draw the  
 150 time until the next event,  $rt$ , from an exponential distribution whose rate parameter is the sum of the  
 rates of all events, such that  $rt \sim \text{Exp}(\sum_j v_j)$ . Then, we randomly determine which event occurred,  
 152 where the probability for event  $k$  is  $p_k = v_k / \sum_j v_j$ . Finally, we update the number of cells of each  
 genotype according to the event that occurred and update the time from  $t$  to  $t + rt$ . We repeat these  
 154 iterations until either the population becomes extinct (the number of cells of all genotypes is zero) or

the number of mutant cells is high enough so that their extinction probability is  $< 0.1\%$ , that is, until

$$m_t > \left\lceil \frac{3 \log 10}{\log(\lambda_m/\mu_m)} \right\rceil + 1,$$

which we obtain by solving  $1 - (1 - p_m)^{m_t} = 0.999$  for  $m_t$  with  $p_m = r_m/\lambda_m$  as the probability that a single mutant escapes stochastic extinction (Appendix A).

When simulations are slow (e.g., due to large population size) with runtimes in the order of days, we use  $\tau$ -leaping (Gillespie, 2001), where we assume that the change in the number of cells of genotype  $k$  in a fixed time interval  $rt$  is Poisson distributed with mean  $v_k rt$ . If the number of cells of genotype  $k$  becomes negative, we change it to zero.

**Parameterization.** We parametrize most of our simulations by considering melanoma cells and rely on Rew and Wilson (2000) and Bozic et al. (2013) for the division and death rates, respectively. Rew and Wilson (2000) report *in vivo* measurements of the potential doubling times (the waiting time for the number of cells in the tumor to double, disregarding cell death) for a large set of cancer types. The division rate is obtained as  $\lambda = \log 2/T \approx 0.1$  per day. We take this to be the division rate for sensitive and assume that mutant cells, which are resistant to therapy, have the same division rate. Indeed, doubling times for tumors after relapse is lower than that of primary tumors for a variety of tissues (Rodgers et al., 2024, Tezuka et al., 2007) and metastatic melanoma has been shown to grow faster than primary melanoma (Carlson, 2003).

Bozic et al. (2013) report the growth rate  $r_s$  for sensitive melanoma cancer cells, from patient data, from which they deduce the death rate  $0.11 \leq \mu_s \leq 0.17$ . We use  $\mu_s = 0.14$  per day. Additionally, they observed the growth rate of cancer cells before treatment to be 0.01, which we use as the growth rate of mutant cells, which are resistant to the drug. Thus, we use  $\mu_m = 0.1 - 0.01 = 0.09$  per day as the death rate for mutant cells.

The aneuploid death rate  $\mu_a$  is set to the mutant death rate,  $\mu_m = 0.09$  per day, assuming aneuploidy increases resistance to the drug, such as cisplatin, by antagonizing cell division (Replogle et al., 2020). For the aneuploid growth rate to be intermediate between those of sensitive and mutant cells,  $r_s \ll r_a \ll r_m$ , we set the aneuploid division rate to be  $0.06 \leq \lambda_a \leq 0.1$ . In most of our simulations, we use  $\lambda_a = 0.0899$  per day, so that aneuploid cells are tolerant and aneuploidy can only act as an evolutionary “stepping stone” for the generation of the resistant mutant that rescues the tumor (note that this mutant will occur on the background of an aneuploid genotype).

We also consider breast cancer cells, relying on Salehi et al. (2021), who studied multiple TNBC PDX clones (triple-negative breast cancer patient-derived xenografts.) We chose three clones for which Salehi et al. (2021) report their relative Wrightian fitness,  $1 + s$ , in the presence of the drug cisplatin: TNBC-SA609 clone A with  $1 + s = 1.047$ , TNBC-SA1035 clone H with  $1 + s = 1.02$ , and TNBC-SA535 clone H with  $1 + s = 1.01$ . The growth rate  $r$ , or the Malthusian fitness, is the log of the Wrightian fitness (Wu et al., 2013). We therefore have the following set of equations:  $1.047 = \exp(r_{SA609} - r_s)$ ,  $1.02 = \exp(r_{SA1035} - r_s)$ ,  $1.01 = \exp(r_{SA535} - r_s)$ . The growth rate of breast cancer cells in the absence of the drug is 0.0085 per day (Spratt et al., 1996). The doubling time of breast cancer cells in the absence of cellular death is 8.2 days (Rew and Wilson, 2000). Thus, the division rate of breast cancer cells in the absence of the drug is  $\log(2)/8.2 = 0.0845$  per day, and their death rate is 0.076 per day. Salehi et al. (2021) report relative fitness for the aneuploid clones rather than division and growth rate. We, therefore, use the above estimates from breast cancer cells in the absence of drugs for the fittest clone, TNBC-SA609 clone A, and solve the set of equations assuming that the drug affects death rather than division and that mutant cells have the same division and death rates as the fittest aneuploid cells of TNBC-SA609 clone A. We therefore have  $\lambda_s = \lambda_a = \lambda_m = 0.0845$

for all clones,  $\mu_s = 0.1215$ ,  $\mu_{SA609} = 0.076$ ,  $\mu_{SA1035} = 0.1015$ ,  $\mu_{SA535} = 0.1115$ , and  $\mu_m = 0.076$ . These estimates are approximate at best, and we hope that future experimental research could provide accurate estimates of these quantities.

The missegregation rate in cancer cells is estimated to be between  $2.5 \times 10^{-4} - 10^{-2}$  per chromosome per cell division (Shi and King, 2005, Thompson and Compton, 2008). Ippolito et al. (2021) observed that trisomy in Chr 2 and Chr 6 are most likely to confer increased resistance against the anti-cancer drug vemurafenib for A375 cells. We assume each of these trisomies is formed at the most likely rate, and as a result, we use  $\tilde{u} = 10^{-3}$  per cell division as the chromosome missegregation rate in the drug-free environment. Some drugs are known to increase chromosome instability (Mason et al., 2017, Wang et al., 2019). Specifically, Lee et al. (2016) estimated the effect of different anti-cancer drugs on the missegregation rate and found a 3-50-fold increase. We thus assume an anti-cancer drug that causes a 10-fold increase in the chromosome missegregation rate, which gives us  $u = 10^{-2}$  per cell division. We assume the mutation rate is  $10^{-7}$  per gene per cell division (Loeb, 2001), and since we assume that a single target gene confers resistance to the drug, we use  $v = 10^{-7}$  per cell division.

To estimate the fitness cost of aneuploidy,  $c$ , we note that Lukow et al. (2021) mixed sensitive and aneuploid A375 melanoma cells at 1 : 1 ratio, cultured them in a drug-free environment, and observed the ratio evolve as a function of time with the aneuploid cells declining to 15% after 24 days. Thus, our estimate for the fitness cost is  $c = |\log(0.15/(1 - 0.15)) / 24| \approx 0.07$  per day (Chevin, 2011). We estimate the fraction of aneuploid cancer cells in the pre-treatment environment using the formula  $f = \tilde{u}\lambda_s/c$ , which produces an estimate of  $f = 10^{-3} \times 10^{-1}/0.07$ , that is, 0.14% of pre-treatment cancer cells have the beneficial aneuploidy of interest.

Note that when we refer to drug-sensitive cells, we include those cells that have any aneuploidy that does not affect fitness in the presence of the drug (see Table 1). Additionally, we focus on mutations that confer resistance, neglecting deleterious mutations (which are more common). We assume deleterious mutations and other aneuploidies occur at similar rates across genotypes and therefore neglect their effect on the dynamics.

**Density-dependent growth.** In most of our analysis, we assume that cells from the initial population divide and die independently of each other. However, these cells will compete for resources. We assume this competition can be ignored because the drug will cause the cell density to rapidly drop below the carrying capacity where competition is important. To test this assumption, we simulate a logistic growth model, with division and death rates given by

$$\begin{aligned}\lambda'_s &= \lambda_s, \\ \mu'_s &= \mu_s + \lambda_s \frac{s + a + m}{K}, \\ \lambda'_a &= \lambda_a, \\ \mu'_a &= \mu_a + \lambda_a \frac{s + a + m}{K}, \\ \lambda'_m &= \lambda_m, \\ \mu'_m &= \mu_m + \lambda_m \frac{s + a + m}{K},\end{aligned}$$

where  $K$  is the tumor carrying capacity. The effective carrying capacity in this model is  $K_e = Kr_a/\lambda_a \approx 10^6$  for  $K = 10^8$ ,  $\lambda_a = 0.0901$ ,  $\mu_a = 0.09$ , where we define the effective carrying capacity to be the population size at which the aneuploid division rate is equal to the aneuploid death rate.

**Code and data availability.** All source code is available online at <https://github.com/yoavram-lab/EvolutionaryRescue>.

## 236 Results

### Evolutionary rescue probability

238 In our model, *evolutionary rescue* occurs when drug-resistant cells appear and establish (avoid random  
 extinction) in the population ( $m_t \gg 1$ ) before the population becomes extinct ( $s_t = a_t = m_t = 0$ ).  
 240 Aneuploidy may contribute to evolutionary rescue by either preventing (when  $r_a > 0$ ) or delaying  
 (when  $0 > r_a > r_s$ ) the extinction of the population before mutant cells appear and establish. We  
 242 assume independence between clonal lineages starting from an initial population of  $N$  sensitive cells  
 (we check the effect of density-dependent growth on our results below) and therefore, we use multi-  
 244 type branching processes to model the dynamics of the cancer cell population. Multi-type branching  
 process models the growth and evolution of populations with distinct types, capturing dynamics like  
 246 mutation and selection. In evolutionary rescue, it predicts the probability of population survival by  
 tracking adaptive mutations that emerge and spread under environmental stress. Define  $p_s$  as the  
 248 probability that a lineage starting from a single drug-sensitive cell avoids extinction by acquiring drug  
 resistance. Thus,  $N^* = 1/p_s$  is the threshold tumor size above which evolutionary rescue is likely  
 250 (Iwasa et al., 2003), and the rescue probability is given by

$$p_{\text{rescue}} = 1 - (1 - p_s)^N \approx 1 - e^{-Np_s} = 1 - e^{-N/N^*}, \quad (1)$$

252 where the approximation  $(1 - p_s) \approx e^{-p_s}$  assumes that  $p_s$  (but not necessarily  $Np_s$ ) is small. Indeed,  
 when  $N < 1/p_s$ , then the probability for evolutionary rescue is  $p_{\text{rescue}} \approx Np_s$ , and when  $N > 1/p_s$ , it  
 254 is  $p_{\text{rescue}} \approx 1$ , justifying the definition of  $N^*$  as the threshold tumor size for evolutionary rescue.

We use multi-type branching-process theory to find approximate expressions eqs. (A4), (A7)  
 256 and (A11) for  $p_s$  in three distinct scenarios (Appendix A). Substituting these into  $N^* = 1/p_s$ , we  
 find approximations for the threshold tumor size,  $N^*$ . In these approximations, an important quantity  
 258 is  $T^* = \sqrt{\lambda_m/4v\lambda_a^2r_m}$ , which is the critical time an aneuploid lineage needs to survive to produce a  
 resistant mutant that avoids random extinction. First, if aneuploidy is sufficiently rare ( $u\lambda_aT^* < 1$ ), or if  
 260 aneuploidy is rare ( $u\lambda_a < -r_a$ ) and sensitive to the drug ( $r_aT^* < -1$ ), then it is likely that evolutionary  
 rescue will occur through a direct resistance mutation in a sensitive cell without aneuploidy playing a  
 262 role in the adaptive dynamics, such that

$$N_m^* \approx \frac{|r_s| \lambda_m}{v\lambda_s r_m}, \quad (2)$$

264 which is similar to a classical result by Orr and Unckless (2008). Here,  $|r_s|/(v\lambda_s)$  is the ratio of the  
 rate at which sensitive cells decrease in number and the rate at which they are mutating. Notably, the  
 266 aneuploidy parameters ( $u, \lambda_a, \mu_a$ ) do not affect  $N_m^*$ .

Otherwise, aneuploidy is frequent enough ( $u\lambda_a > \max(-r_a, 1/T^*)$ ) to affect the evolution of  
 268 drug resistance. The threshold tumor size can be approximated by one of the following scenarios,  
 depending on  $r_aT^*$ , which represents the change in the aneuploid log-population size during the critical  
 270 time,

$$N_a^* \approx \frac{|r_s|}{u\lambda_s} \cdot \begin{cases} \frac{|r_a| \lambda_m}{v\lambda_a r_m}, & r_aT^* \ll -1 \text{ (tolerant aneuploids),} \\ 2\lambda_aT^*, & -1 \ll r_aT^* \ll 1 \text{ (stationary aneuploids),} \\ \frac{\lambda_a}{r_a}, & r_aT^* \gg 1 \text{ (resistant aneuploids).} \end{cases} \quad (3)$$

272 This equation is equivalent to eq. A3 of Iwasa et al. (2004) and to eq. 8 of Osmond et al. (2020) with  
 the distribution of fitness effects set to a delta function; our “tolerant”, “stationary”, and “resistant”  
 274 scenarios correspond to Osmond et al. (2020)’s “sufficiently subcritical”, “sufficiently critical”, and  
 “sufficiently supercritical”, respectively. These approximations are accurate when compared to results

276 of stochastic evolutionary simulations (Figures 3 and 4). Our parameterization for triple-negative  
breast cancer clones suggests that TNBC-SA609 clone A is resistant to the drug ( $r_a T^* > 500$ ),  
278 whereas TNBC-SA1035 clone H and TNBC-SA535 clone H are tolerant ( $r_a T^* < -1000$ ).

In the first scenario, the treatment effectively kills aneuploid cells but not as quickly as it kills  
280 sensitive cells. In the second scenario, aneuploid cells are sufficiently resistant, and the expected  
size of each aneuploid lineage is roughly one. In both of these scenarios, aneuploidy increases the  
282 probability of rescue by slowing or halting the decrease in the tumor population size, allowing more  
opportunities to produce resistant mutants. In the third scenario, aneuploid cells are sufficiently  
284 resistant for the population to re-grow the tumor without additional resistance mutations. Notably, in  
this scenario the mutant parameters ( $v$ ,  $\lambda_m$ , and  $r_m$ ) do not affect  $N_a^*$  beyond their effect on  $T^*$ . In  
286 all scenarios,  $N_a^*$  is proportional to  $1/u$  such that increasing the missegregation rate  $u$  will decrease  
the threshold tumor size (Figure 4B). Furthermore, increasing the aneuploid growth rate  $r_a$  (which  
288 appears both in the terms and in the conditions), also reduces the threshold tumor size, with a sharp  
decrease around  $r_a = 0$ , but the effect is minor when  $|r_a|$  is small compared to  $T^*$  as this would result  
290 in the second scenario where  $dN_a^*/dr_a = 0$  (Figure 4A). The tumor threshold size decreases with the  
mutation rate in the first and second scenarios:  $N_a^*$  is proportional to  $1/v$  in the first scenario (tolerant  
292 aneuploids) and to  $\sqrt{1/v}$  in the second scenario (stationary aneuploids). Furthermore, the growth  
rate  $r_a < 0$  that allows tolerant aneuploids to rescue the tumor is between  $-u\lambda_a$  and  $-1/T^*$ , which is  
294 proportional to  $-\sqrt{v}$ . Thus, increasing the mutation rate  $v$  will decrease the tumor threshold size  $N_a^*$ ,  
making evolutionary rescue more likely.

296 Using eqs. (2) and (3), we can find the ratio of threshold tumor size for rescue via aneuploidy ( $u$   
is high) or via direct mutation ( $u$  is low),

$$298 \quad \frac{N_a^*}{N_m^*} \approx \begin{cases} \frac{|r_a|}{u\lambda_a}, & r_a T^* \ll -1 \text{ (tolerant aneuploids),} \\ \frac{1}{u} \left( v \frac{r_m}{\lambda_m} \right)^{1/2}, & -1 \ll r_a T^* \ll 1 \text{ (stationary aneuploids),} \\ v \frac{r_m}{\lambda_m} \left( u \frac{r_a}{\lambda_a} \right)^{-1}, & r_a T^* \gg 1 \text{ (resistant aneuploids).} \end{cases} \quad (4)$$

Importantly, when this threshold is smaller than 1, aneuploidy is expected to play a role in evolutionary  
300 rescue, as it reduces the threshold tumor size needed for rescue. As expected, this ratio increases with  
the mutation rate  $v$  and decreases with the aneuploidy rate  $u$ . In the first scenario,  $|r_a|/u\lambda_a$  is the  
302 ratio of the expected time for an aneuploid lineage to appear,  $1/u\lambda_a$ , and the expected time until that  
lineage disappears,  $1/|r_a|$ . In the third scenario,  $\left( v \frac{r_m}{\lambda_m} \right) / \left( u \frac{r_a}{\lambda_a} \right)$  is the ratio of the rates of appearance  
304 of resistant mutants that avoid extinction and partially resistant aneuploids that avoid extinction. In  
the second scenario,  $\frac{1}{u} \left( v \frac{r_m}{\lambda_m} \right)^{1/2} = \sqrt{\frac{r_a}{u\lambda_a} v \frac{r_m}{\lambda_m} \left( u \frac{r_a}{\lambda_a} \right)^{-1}}$ , which is the geometric mean of the first and  
306 third scenarios.

Interestingly, increasing both the aneuploid division rate,  $\lambda_a$ , and the aneuploid death rate,  $\mu_a$ ,  
308 such that the growth rate  $r_a$  remains constant, leads to a decrease in  $T^*$ , pushing the system to the  
second scenario. This is because increasing  $\lambda_a$  causes a decrease in  $T^*$  as it increases the effective  
310 mutation rate  $v\lambda_a$  (as mutations mostly occur during division) and a lineage does not have to survive  
as long in order to generate a successful mutant. In the second scenario, the threshold tumor size  $N_a^*$   
312 is unaffected by the division rate  $\lambda_a$  (i.e.,  $d\lambda_a T^*/d\lambda_a = 0$ ). Thus, if aneuploid cells rapidly die due to  
the drug but compensate by rapidly dividing, increasing the division rate will *not* facilitate adaptation.

314 We can categorize tumors by their size: small tumors with size  $N < N_a^*$  that are unlikely to survive  
treatment, intermediate tumors with size  $N_a^* < N < N_m^*$  that rely on aneuploidy for evolutionary  
316 rescue, and large tumors with size  $N > N_m^*$  that could overcome the effect of drug treatment without  
aneuploidy. For the parameter values in Table 1 with  $\lambda_a = 0.0899$ ,  $\mu_s = 0.14$ ,  $u = 10^{-2}$ ,  $v = 10^{-7}$ ,



we are in the tolerant aneuploid scenario, and substituting in eqs. (2) and (3), we have  $N_a^* \approx 4 \times 10^6$  and  $N_m^* \approx 4 \times 10^7$ . Hence, we obtain the ratio  $N_a^*/N_m^* \approx 0.11$  (eq. (4)), that is, aneuploidy reduces the threshold tumor size by approximately 89%. Interestingly, the threshold between small and intermediate tumors,  $N_a^*$ , is similar to the tumor detection threshold of  $4.19 \times 10^6$  cells for a wide variety of tumors (Avanzini and Antal, 2019). We note that vemurafenib-treated melanomas (i.e. melanomas with sizes above the detection threshold) have a probability  $> 50\%$  to relapse (Handa et al., 2022, Piejko et al., 2023).

Aneuploidy may lead to an increased mutation rate in cancer cells (Garribba et al., 2023, Janssen et al., 2011, Passerini et al., 2016). Thus, we extended our model to account for this in Appendix H. We find that increasing the mutation rate in aneuploid cells by one order of magnitude leads to a decrease in the threshold tumor size of approximately one order of magnitude. Also, it transitions the system from the first scenario (tolerant aneuploids) to the second scenario (stationary aneuploids) without changing the aneuploid growth rate,  $r_a$ .

In our analysis, we used branching processes, which assume that growth (division and death) is density-independent. However, growth may be limited by resources (oxygen, nutrients, etc.) and therefore depend on cell density. We performed stochastic simulations of a logistic growth model with a carrying capacity. We find that our density-independent approximations agree with the results of simulations with density-dependent growth for biologically relevant parameter values (Figure S1).

**Standing vs. *de novo* genetic variation.** We assumed that at the onset of drug treatment the initial tumor consisted entirely of drug-sensitive cells but aneuploidy is likely produced even before the onset of treatment at some rate  $\tilde{u}$ , which may be lower in the absence of drugs,  $\tilde{u} < u$  (Mason et al., 2017, Wang et al., 2019). Aneuploidy likely confers a fitness cost  $c$  in the absence of drugs (Giam and Rancati, 2015, Replogle et al., 2020). If the number of cells in the tumor  $N$  is large (as expected if the tumor is treated with a drug), there may already be a fraction  $f \approx \tilde{u}\lambda_s/c$  of aneuploid cells in the population (here we assume that the drug affects the sensitive death rate but not the division rate and therefore we use  $\lambda_s$  for the sensitive division rate in the drug-free environment).

Therefore, the threshold tumor size for rescue by standing genetic variation,  $\tilde{N}_a^*$ , is similar to the threshold for rescue by *de novo* variation,  $N_a^*$ , except that the sensitive growth rate  $|r_s|$  is replaced by the cost of aneuploidy  $c$ , such that

$$\frac{\tilde{N}_a^*}{N_a^*} = \frac{u}{\tilde{u}} \frac{c}{|r_s|}. \quad (5)$$

This result has been previously reported by Orr and Unckless (2008) and Martin et al. (2013) for one-step evolutionary rescue. Comparing this approximation of  $\tilde{N}_a^*/N_a^*$  to results of stochastic simulations, we find that the approximations are accurate (Figure 5). Standing genetic variation will drive evolutionary rescue if sensitive cells die rapidly (growth rate  $r_s$  is negative) due to a strong effect of the drug on sensitive cells or if the cost of aneuploidy in the drug-free environment,  $c$ , is small. In contrast, *de novo* aneuploid cells will have a greater contribution to rescue if the cost of aneuploidy,  $c$ , is large, the effect of the drug on sensitive cells is weak ( $r_s$  is close to zero), or if the drug induces the appearance of aneuploid cells ( $u > \tilde{u}$ ). For example, with  $\lambda_s = 0.1$ ,  $\mu_s = 0.14$ ,  $u = 10^{-2}$ ,  $\tilde{u} = 10^{-3}$ , and  $c = 0.07$ , the ratio of the threshold tumor sizes for standing vs. *de novo* variation is  $\tilde{N}_a^*/N_a^* \approx 17.5$ , which means that *de novo* genetic variation is the main driver of evolutionary rescue.

358 Using eqs. (2), (3) and (5), we can find the ratio of threshold tumor size for rescue via standing genetic variation to the threshold for rescue via direct mutation,

$$360 \quad \frac{\tilde{N}_a^*}{N_m^*} = \frac{\tilde{N}_a^*}{N_a^*} \frac{N_a^*}{N_m^*} \approx \frac{c}{|r_s|} \begin{cases} \frac{|r_a|}{\tilde{u}\lambda_a}, & r_a T^* \ll -1 \text{ (tolerant aneuploids),} \\ \frac{1}{\tilde{u}} \left( v \frac{r_m}{\lambda_m} \right)^{1/2}, & -1 \ll r_a T^* \ll 1 \text{ (stationary aneuploids),} \\ v \frac{r_m}{\lambda_m} \left( \tilde{u} \frac{r_a}{\lambda_a} \right)^{-1}, & r_a T^* \gg 1 \text{ (resistant aneuploids).} \end{cases} \quad (6)$$

Evolutionary rescue through direct mutation is more likely if the cost of aneuploidy,  $c$ , is large or the effect of the drug  $r_s$  is small. In contrast, standing genetic variation will drive adaptation if the pre-treatment chromosome missegregation rate,  $\tilde{u}$ , is large. The ratio does not depend on the rate of chromosome missegregation induced by the drug,  $u$ . However, if the aneuploid growth rate,  $r_a$ , increases, evolutionary rescue is driven by standing genetic variation. For the parameter values of  $\lambda_s = 0.1$ ,  $\lambda_a = 0.0899$ ,  $\lambda_m = 0.1$ ,  $\mu_s = 0.14$ ,  $\mu_a = 0.09$ ,  $\mu_m = 0.09$ ,  $\tilde{u} = 10^{-3}$ , and  $v = 10^{-7}$ , we are in the first scenario (tolerant aneuploids) and obtain the ratio  $\tilde{N}_a^*/N_m^* \approx 1.94$ , which means that standing genetic variation does not drive evolution of drug resistance when compared to direct mutation. We note that for larger values of the pre-treatment chromosome missegregation rate,  $\tilde{u}$ , which are consistent with empirical studies (Table 1), standing genetic variation can drive adaptation when compared to direct mutation.

## 372 Recurrence time due to evolutionary rescue

When evolutionary rescue occurs, the time until the tumor recurs may still be long. We therefore explored the time until the tumor recurs, that is, the time until the tumor reaches its original size,  $N$ . When the expected number of resistant lineages that avoid extinction is small, the expected recurrence time can be estimated by adding two terms: the *mean evolutionary rescue time*, which is the waiting time for the appearance of a resistant lineage that avoids extinction (conditioned on such an event occurring in the first place), and the *mean proliferation time*, which is the expected time for that lineage to grow to  $N$  cells. However, when the expected number of resistant lineages is large, the mean recurrence time cannot be separated into the mean evolutionary rescue time and mean proliferation time because multiple mutant lineages contribute towards the mutant population size reaching the initial tumor size. In this case the dynamics of the number of mutant cells is deterministic and can therefore be modeled by a system of ordinary differential equations (ODE), which describe how the number of mutant cells changes over time by its time derivative (eq. D2). Of particular interest is the distribution of the evolutionary rescue time and recurrence time with tolerant aneuploid cells ( $r_a T^* \ll 1$ ) given that this represents the two step evolutionary rescue scenario. We focus on the parameter values in Table 1 with  $\lambda_a = 0.0899$  (tolerant aneuploids),  $\mu_s = 0.14$  (intermediate sensitive death rate), and  $v = 10^{-7}$  (high end of the mutation rate).

**Evolutionary rescue time.** We have derived approximations for  $\tau_m$ , the mean evolutionary rescue time without aneuploidy ( $u = 0$ ), and  $\tau_a$ , the mean rescue time with aneuploidy ( $u > 0$ ), both conditioned on evolutionary rescue occurring (Appendix C). These approximations agree with simulation results for small, intermediate, and large tumor sizes (Figures S2 and S6). The mean rescue time with aneuploidy for small and large tumors follows

$$394 \quad \tau_a \approx \begin{cases} -\frac{1}{r_s} - \frac{1}{r_a}, & N \ll N_a^*, \\ \frac{1}{v\lambda_s N} \frac{\lambda_m}{r_m}, & N \gg N_m^*. \end{cases} \quad (7)$$

For small tumors ( $N \ll N_a^*$ ), the mean rescue time is the two-step equivalent of the one-step result from Orr and Unckless (2014, expectation of eq. 18). The mean rescue time (conditioned on rescue

occurring) is a decreasing function of the sensitive and aneuploid growth rates and independent of  
 398 the other model parameters, including tumor size (blue line in Figure S6). This is because if the  
 400 population rapidly declines but is then rescued, than the resistance mutation must have appeared early;  
 In our focus parameter regime, we have  $r_s = -0.04$  and  $r_a = -10^{-4}$ , such that the mean rescue time is  
 402 mainly determined by the aneuploid growth rate, and  $\tau_a \approx 10^4$  days (eq. (7)).

For large tumors ( $N \gg N_m^*$ ), the dynamics are equivalent to a scenario where rescue mutations  
 404 appear at a constant rate, and the mean rescue time is independent of the aneuploid parameters ( $u$ ,  
 $\lambda_a$ , and  $r_a$ ). Increasing the per division mutation rate,  $v$ , leads to the faster appearance of a rescue  
 406 mutations and hence reduced mean rescue time. Increasing the tumor size leads to shorter mean rescue  
 time, as more sensitive cells can mutate to become resistant.

Given that a fraction  $f \approx 0.14\%$  of the initial cancer cell population is expected to have beneficial  
 408 aneuploidy even before the onset of drug treatment, we want to know whether the mean evolutionary  
 410 rescue time is affected by the standing genetic variation. We calculated the mean evolutionary  
 rescue time with standing genetic variation,  $\tilde{\tau}_a$  (eq. (C10)), and compared our result with simulations  
 412 (Figure S9). We find that standing genetic variation does not significantly affect the mean evolutionary  
 rescue time.

We calculate the probability that a rescue mutation has been generated by time  $t$  in Appendix E.  
 414 This allows us to examine whether aneuploidy promotes or delays evolutionary rescue. We find that  
 416 aneuploidy promotes evolutionary rescue after  $1/r_s \approx 100$  days, at a time when no more rescue  
 mutations are generated through mutations in sensitive cells (Figure 6A). Thus, aneuploidy increases  
 418 the *window of opportunity* for evolutionary rescue. This can have a counter-intuitive outcome:  
 conditioned on the rescue of the tumor, tumors rescued by aneuploid cells may acquire rescue mutations  
 420 later than those rescued by sensitive cells.

**Recurrence time.** We next approximated the mean time for the population of mutant cancer cells to  
 422 reach the initial, pre-treatment population size  $N$ , which we denote the recurrence time  $\tau_a^r$  (eqs. (D1),  
 (D4) and (7)),

$$424 \quad \tau_a^r \approx \begin{cases} -\frac{1}{r_s} - \frac{1}{r_a} + \frac{\log p_m N}{r_m}, & N \ll N_a^*, \\ \frac{1}{r_m} \log \frac{r_m - r_s}{v \lambda_s}, & N \gg N_m^*, \end{cases} \quad (8)$$

where  $p_m$  is the probability that a lineage starting from a single mutant cell escapes stochastic  
 426 extinction. Figures 7 and S7 show the agreement between our approximations and simulation results.  
 For small tumors ( $N \ll N_a^*$ ), the mean recurrence time can be approximated as the sum of the mean  
 428 time for the first rescue mutation to appear ( $\tau_a$ ) and the additional mean time for its lineage to reach size  
 $N$ . This additional time is the equivalent of Orr and Unckless (2014)'s " $t_{\text{return}}$ " (their eq. 23). It grows  
 430 logarithmically with tumor size  $N$  and may be the same order of magnitude as the mean evolutionary  
 rescue time. Increasing the sensitive  $r_s$ , aneuploid  $r_a$  and mutant  $r_m$  growth rates decreases the  
 432 recurrence time.

For large tumors ( $N \gg N_m^*$ ), the dynamics of the number of mutant cells is deterministic, and the  
 434 mean recurrence time becomes independent of the initial tumor size  $N$ . Increasing either the mutant  
 growth rate,  $r_m$ , or the mutation rate,  $v$ , decreases the time for the tumor to rebound to its initial size.  
 436 Drugs that significantly increase the death rate of sensitive cells,  $\mu_s$ , but do not affect their division  
 rate,  $\lambda_s$ , delay cancer recurrence. Additionally, decreasing the sensitive division rate will also the  
 438 cancer recurrence time. Consequently, patients treated with such drugs may require a longer period  
 of monitoring to guarantee the effectiveness of the treatment. Drugs that significantly increase the  
 440 division rate of sensitive cells,  $\lambda_s$ , but do not affect their death rate,  $\mu_s$ , decrease cancer recurrence  
 times (conditioned on evolutionary rescue).

442 We note that, for small and large tumors, when  $N \ll N_a^*$  or  $N \gg N_m^*$ , the asymptotic expressions  
 444 for the mean recurrence time are independent of the chromosome missegregation rate  $u$ , and therefore,  
 the rate at which the drug induces aneuploidy has no effect on the time for the tumor to rebound to its  
 initial size  $N$ .

446 Appendix F gives us the probability that a mutant cancer cell population has not reached size  $N$   
 by time  $t$ . Figure 6B shows agreement between our approximations and simulation results for various  
 448 values of  $N$ . Additionally, we derive the distribution of the recurrence time for a small tumor with  
 $N = 10^6$  cells, noting that the distribution is wide and right-skewed (Figure S4). It is highly unlikely  
 450 to observe the recurrence of cancer at times smaller than  $\frac{1}{r_m} \log \frac{r_m - r_s}{v \lambda_s} \approx 1500$  days for the parameter  
 values in Table 1 with  $\lambda_a = 0.0899$ ,  $\mu_s = 0.14$ , and  $v = 10^{-7}$  and independent of initial tumor size  
 452  $N$  (Figure 6B).

The detection time  $\tau_a^M$  is defined as the time for the tumor size to reach detection threshold  $M$ . We  
 454 derive the mean detection time for  $M = 10^7$  in Appendix D. We find that for small and intermediate-  
 sized tumors the mean detection time is approximately equal to the mean recurrence time (i.e.,  $\tau_a^r \approx \tau_a^M$   
 456 for  $N < N_m^*$ ). For large tumors the mean detection time  $\tau_a^M$  decreases logarithmically with tumor size  
 $N$ , while the recurrence time  $\tau_a^r$  is constant (Figure S8). For large tumors we also have  $M < N_m^* < N$ ,  
 458 so the mean detection time is shorter compared to the mean recurrence time, that is, the resistant tumor  
 may be detected before recovering back to its initial size.

## 460 Discussion

We have modeled a tumor—a population of cancer cells—exposed to drug treatment that causes it to  
 462 decline in size toward potential extinction. In this scenario, the tumor can be “evolutionarily rescued”  
 or escape extinction via two paths. In the direct path, a drug-sensitive cell acquires a mutation or  
 464 aneuploidy that confers resistance and allows it to grow rapidly. In the indirect path, a sensitive cell  
 first becomes aneuploid, which diminishes the drug’s effect, and then an aneuploid cell acquires a  
 466 mutation that confers resistance (Figure 1).

Using multi-type branching processes, we derived the probability of evolutionary rescue of the  
 468 tumor under the effects of aneuploidy, ranging from tolerance to partial resistance. We obtained exact  
 and approximate expressions for the probability of evolutionary rescue (eq. (1)). Our results show that  
 470 the probability of evolutionary rescue increases with the initial tumor size  $N$ , the drug-sensitive growth  
 rate  $r_s$ , the mutation rate  $v$ , and the aneuploidy rate  $u$ . Notably, the latter indicates that aneuploidy,  
 472 even when it only provides tolerance, increases the probability that the tumor will be rescued, as long  
 as it is produced fast enough (Figure 3A, eq. (4)).

474 When aneuploid cells are partially resistant to the drug ( $r_s \ll 0 \ll r_a \ll r_m$ ), aneuploidy  
 itself rescues the population (Figure 4A). When aneuploidy only provides tolerance to the drug  
 476 ( $r_s \ll r_a \ll 0 \ll r_m$ ), it cannot rescue the population. Instead, if the aneuploidy rate is fast enough  
 (eq. (4)) then it may act as a “stepping stone” through which the resistant mutant can appear more  
 478 easily, given that the number of aneuploid cells declines slower than the number of drug-sensitive cells  
 (Figure 2). In this scenario, aneuploidy provides two advantages. First, it delays the extinction of the  
 480 population, providing more time for the appearance of a resistance mutation. Second, it increases the  
 population size relative to a drug-sensitive population, providing more cells in which mutations can  
 482 occur. Together, this increases the cumulative number of mutants that arise (i.e.,  $Nuv\lambda_s\lambda_a/|r_s r_a|$ ).

We find that aneuploidy can significantly affect evolutionary rescue by reducing the threshold  
 484 tumor size by several orders of magnitude, even when aneuploidy only provides tolerance, provided  
 that the aneuploidy rate is high enough,  $\lambda_a u > |r_a|$  (Figure 3A, eq. (4)). When the number of cells in  
 486 the tumor is large enough (i.e.,  $N \gg N_m^* \approx 4 \times 10^7$ ), a resistance mutation will occur in drug-sensitive

cells before these cells become extinct. Therefore, large tumors are likely to be rescued with or without  
488 aneuploidy. Anti-cancer drugs are often used as adjuvant therapy after resection, in which case the  
490 number of cells in the tumor may be below the detection threshold of  $\sim 10^7$  (Bozic et al., 2013). In  
492 these cases, aneuploidy can have a crucial role in the evolutionary rescue of the tumor and, therefore,  
in cancer recurrence. Indeed, secondary tumors are estimated to cause the majority of cancer-related  
494 deaths (Chaffer and Weinberg, 2011). The importance of aneuploidy in the evolutionary rescue of  
secondary tumors is reinforced by the fact that metastases have been shown to have a chromosome  
misseggregation rate two to three orders of magnitude higher compared to primary tumors (Kimmel  
et al., 2023).

496 As an example, we have parameterized our model using estimates from three triple-negative  
breast cancer (TNBC) clones under drug therapy. We find that TNBC clones are either in the first  
498 scenario, in which aneuploidy provides a partial or full resistance to the drug, or the third scenario, in  
which aneuploidy provides tolerance to the drug. It remains to be seen which tumor type and drug  
500 combinations produce stationary aneuploidies. Comparing the probability of evolutionary rescue  
between different tumors (Figure 3B) suggests that some TNBC clones have a much higher probability  
502 of relapsing compared to melanoma and other TNBC clones. Notably, the probability of relapse in  
TNBC patients is higher than 50% in the first 3-5 years after diagnosis (Taushanova et al., 2023),  
504 whereas in melanoma patients it is approximately 10-20% in the first 5 years (Von Schuckmann et al.,  
2019, Wan et al., 2022).

506 Given that the mean time for secondary tumors to adapt to anti-cancer drugs can be of the order  
of 1,000 days (Figure S2A), aneuploidy can explain the reappearance of cancer even after initial  
508 remission. The theoretical prediction for the mean rescue time of tumors smaller than  $10^8$  cells  
is greater than 4 years, consistent with previous estimates of the recurrence time of tumors after  
510 resection (Avanzini and Antal, 2019). We found that aneuploidy complements evolutionary rescue  
through direct mutation because it produces rescue mutations mostly after the number of sensitive  
512 cells has decreased to a point where a direct mutation is no longer a feasible option for evolutionary  
rescue (Figure 6A).

514 We hypothesized that standing genetic variation (the existence of aneuploid cancer cells in the  
tumor before the onset of therapy) could facilitate evolutionary rescue by reducing the waiting time  
516 for the appearance of aneuploid cells. We found that a drug that reduces the sensitive growth rate and  
does not significantly increase the chromosome misseggregation rate will likely lead to evolutionary  
518 rescue through standing genetic variation (Figure 5 and eq. (5)). If the fraction of tumor cells that have  
the beneficial aneuploidy is  $f \gg u\lambda_s/r_s \approx 2.5\%$ , then evolutionary rescue is more likely to occur  
520 via standing variation rather than through *de novo* aneuploidy. For the parameter values we focus  
on in our examples (Table 1), this fraction is an order of magnitude lower, and therefore, we expect  
522 evolutionary rescue to occur primarily by *de novo* aneuploidy.

Similar to Osmond et al. (2020), we find that two-step rescues can be more likely than simple  
524 one-step rescues, because the mutation rate to stepping-stone (aneuploid) genotypes can be much  
higher than that to fully resistant genotypes. The “stationary” scenario, in which the aneuploid growth  
526 rate is close to zero in the presence of the drug, is particularly interesting. Although this may seem  
like a small region of parameter space in a general model of evolutionary rescue (Fig. 4A, inset), it  
528 could be biologically significant for some tumors under specific drug therapies. Our results suggest  
that identifying aneuploidies that are tolerant or stationary may be worthwhile, as they may enhance  
530 the probability of rescue (Figure 3A) and extend the window of opportunity for rescue (Figure 6).

Experiments could test our model predictions. For example, to assess the effect of initial tumor  
532 size on the probability of evolutionary rescue, a large culture mass can be propagated from a single  
cancer cell in permissive conditions and then diluted to a range of starting tumor sizes. Then, the  
534 extinction or survival of these tumors can be monitored during exposure to anti-cancer drugs that

induce aneuploidy or to saline solution for control (Ippolito et al., 2021). We can then compare the  
536 results of these experiments to predictions of our model to see if tumors with initial size below the  
threshold eq. (3) are more likely to become extinct due to drug exposure. It may also be interesting  
538 to look for the involvement of aneuploidy in evolutionary rescue in other biological systems, such as  
evolution of yeast populations under different stress conditions (Kohanovski et al., 2024, Pompei and  
540 Cosentino Lagomarsino, 2023).

Our model neglects the possibility of back-mutations from aneuploidy to euploidy, and also the  
542 possibility that the fitness of a euploid cell with a resistance mutation may be higher than that of an  
aneuploid cell with the same mutation. Both of these would be expected to reduce the importance  
544 of two-step rescues via aneuploidy. But for the former, unless the rate of loss of extra chromosomes  
is extremely high (for estimates in yeast, see Hose et al. (2024)), comparable in magnitude to the  
546 growth rate  $r_a$ , we expect that its effect on the dynamics will be negligible. The latter possibility, in  
which aneuploidy substantially reduces the mutant growth rate, seems more likely to have an effect.  
548 Including it would be a straightforward extension to our model. In this case, it could actually be  
more important to consider the possibility of the loss of aneuploidy, as one would need to check the  
550 relative rates of the simple *sensitive*  $\rightarrow$  *euploid mutant* path and the three-step *sensitive*  $\rightarrow$  *aneuploid*  
 $\rightarrow$  *aneuploid mutant*  $\rightarrow$  *euploid mutant* path (Kohanovski et al., 2024).

We have assumed that cancer cell lineages are independent and have verified that this is accurate  
552 under simple logistic growth. This assumption neglects the potential effects of spatial structure  
and local interactions, which may be important in solid tumors. Such tumors can be spatially  
554 heterogeneous, with different genotypes inhabiting cellular niches and immune infiltration impacting  
growth in affected regions (Galon et al., 2010, Varrone et al., 2023). This can potentially impact the  
556 probability of evolutionary rescue (Martens et al., 2011).

**558 Conclusions.** Our results quantitatively suggest that aneuploidy can play an important role in tumor  
adaptation to anti-cancer drugs when the tumor size is small or intermediate. Large tumors are  
560 predicted to adapt to anti-cancer drugs through direct mutation. In contrast, smaller tumors are  
predicted to become resistant either directly by aneuploidy or by a resistance mutation occurring in  
562 aneuploid cells that serve as evolutionary “stepping stones”. Thus, therapies that increase the rate of  
aneuploidy in tumors to combat cancer may also promote drug resistance.

## 564 Acknowledgements

We thank Hildegard Uecker for discussions and the editor and three reviewers for comments on the manuscript.  
566 This work was supported in part by the Israel Science Foundation (ISF 552/19, YR), the US–Israel Binational  
Science Foundation (BSF 2021276, YR), Minerva Stiftung Center for Lab Evolution (YR), Ela Kodesz Institute  
568 for Research on Cancer Development and Prevention (RS), the Simons Foundation (Investigator in Mathematical  
Modeling of Living Systems #508600, DBW), the Sloan Foundation (Research Fellowship FG-2021-16667,  
570 DBW), the National Science Foundation (grant #2146260, DBW), the ERC Starting Grant (#945674, UBD).

## References

- Alexander, H. K., Martin, G., Martin, O. Y. and Bonhoeffer, S. (2014), ‘Evolutionary rescue: linking  
theory for conservation and medicine’, *Evolutionary applications* **7**(10), 1161–1179.
- Allen, L. J. (2010), *An introduction to stochastic processes with applications to biology*, CRC press.
- Antia, R., Regoes, R. R., Koella, J. C. and Bergstrom, C. T. (2003), ‘The role of evolution in the  
emergence of infectious diseases’, *Nature* **426**, 658 – 661.

- Avanzini, S. and Antal, T. (2019), ‘Cancer recurrence times from a branching process model’, *PLoS computational biology* **15**(11), e1007423.
- Bakker, B., Schubert, M., Bolhaqueiro, A. C., Kops, G. J., Spierings, D. C. and Foijer, F. (2023), ‘Predicting CIN rates from single-cell whole genome sequencing data using an *in silico* model’, *bioRxiv* pp. 2023–02.
- Barton, G. (1989), *Elements of Green’s functions and propagation: potentials, diffusion, and waves*, Oxford University Press.
- Bell, G. (2017), ‘Evolutionary rescue’, *Annual Review of Ecology, Evolution, and Systematics* **48**(1), 605–627.
- Ben-David, U. and Amon, A. (2020), ‘Context is everything: aneuploidy in cancer’, *Nature Reviews Genetics* **21**(1), 44–62.
- Berman, J. and Krysan, D. J. (2020), ‘Drug resistance and tolerance in fungi’, *Nature Reviews Microbiology* **18**(6), 319–331.
- Bozic, I., Reiter, J. G., Allen, B., Antal, T., Chatterjee, K., Shah, P., Moon, Y. S., Yaquibie, A., Kelly, N., Le, D. T. et al. (2013), ‘Evolutionary dynamics of cancer in response to targeted combination therapy’, *eLife* **2**, e00747.
- Brauner, A., Fridman, O., Gefen, O. and Balaban, N. Q. (2016), ‘Distinguishing between resistance, tolerance and persistence to antibiotic treatment’, *Nature Reviews Microbiology* **14**(5), 320–330.
- Carja, O. and Plotkin, J. B. (2017), ‘The evolutionary advantage of heritable phenotypic heterogeneity’, *Scientific reports* **7**(1), 1–12.
- Carja, O. and Plotkin, J. B. (2019), ‘Evolutionary rescue through partly heritable phenotypic variability’, *Genetics* **211**(3), 977–988.
- Carlson, J. A. (2003), ‘Tumor doubling time of cutaneous melanoma and its metastasis’, *The American journal of dermatopathology* **25**(4), 291–299.
- Chaffer, C. L. and Weinberg, R. A. (2011), ‘A perspective on cancer cell metastasis’, *science* **331**(6024), 1559–1564.
- Chevin, L.-M. (2011), ‘On measuring selection in experimental evolution’, *Biology letters* **7**(2), 210–213.
- Cobbold, C. A. and Stana, R. (2020), ‘Should I stay or should I go: partially sedentary populations can outperform fully dispersing populations in response to climate-induced range shifts’, *Bulletin of Mathematical Biology* **82**(2), 1–21.
- Del Monte, U. (2009), ‘Does the cell number  $10^9$  still really fit one gram of tumor tissue?’, *Cell cycle* **8**(3), 505–506.
- Galon, J., Dieu-Nosjean, M., Tartour, E., Sautes-Fridman, C., Fridman, W. et al. (2010), ‘Immune infiltration in human tumors: a prognostic factor that should not be ignored’, *Oncogene* **29**(8), 1093–1102.
- Garribba, L., De Feudis, G., Martis, V., Galli, M., Dumont, M., Eliezer, Y., Wardenaar, R., Ippolito, M. R., Iyer, D. R., Tijhuis, A. E. et al. (2023), ‘Short-term molecular consequences of chromosome mis-segregation for genome stability’, *Nature Communications* **14**(1), 1353.
- Giam, M. and Rancati, G. (2015), ‘Aneuploidy and chromosomal instability in cancer: a jackpot to chaos’, *Cell division* **10**(1), 1–12.

- Gillespie, D. T. (1976), ‘A general method for numerically simulating the stochastic time evolution of coupled chemical reactions’, *Journal of computational physics* **22**(4), 403–434.
- Gillespie, D. T. (1977), ‘Exact stochastic simulation of coupled chemical reactions’, *The journal of physical chemistry* **81**(25), 2340–2361.
- Gillespie, D. T. (2001), ‘Approximate accelerated stochastic simulation of chemically reacting systems’, *The Journal of chemical physics* **115**(4), 1716–1733.
- Gomulkiewicz, R. and Holt, R. D. (1995), ‘When does evolution by natural selection prevent extinction?’, *Evolution* pp. 201–207.
- Gunnarsson, E. B., De, S., Leder, K. and Foo, J. (2020), ‘Understanding the role of phenotypic switching in cancer drug resistance’, *Journal of theoretical biology* **490**, 110162.
- Handa, S., Lee, J.-O., Derkach, A., Stone, R. M., Saven, A., Altman, J. K., Grever, M. R., Rai, K. R., Shukla, M., Vemuri, S. et al. (2022), ‘Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy’, *Blood, The Journal of the American Society of Hematology* **140**(25), 2663–2671.
- Harris, T. E. (1963), *The theory of branching processes*, Vol. 6, Springer Berlin.
- Harsch, M. A., Zhou, Y., HilleRisLambers, J. and Kot, M. (2014), ‘Keeping pace with climate change: stage-structured moving-habitat models’, *The American Naturalist* **184**(1), 25–37.
- Hose, J., Zhang, Q., Sharp, N. P. and Gasch, A. P. (2024), ‘On the rate of aneuploidy reversion in a wild yeast model’, *Genetics* p. iyae196.
- Ippolito, M. R., Martis, V., Martin, S., Tijhuis, A. E., Hong, C., Wardenaar, R., Dumont, M., Zerbib, J., Spierings, D. C., Fachinetti, D. et al. (2021), ‘Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy’, *Developmental cell* **56**(17), 2440–2454.
- Iwasa, Y., Michor, F. and Nowak, M. A. (2003), ‘Evolutionary dynamics of escape from biomedical intervention’, *Proceedings of the Royal Society of London. Series B: Biological Sciences* **270**(1533), 2573–2578.
- Iwasa, Y., Michor, F. and Nowak, M. A. (2004), ‘Evolutionary dynamics of invasion and escape’, *Journal of Theoretical Biology* **226**(2), 205–214.
- Janssen, A., Van Der Burg, M., Szuhai, K., Kops, G. J. and Medema, R. H. (2011), ‘Chromosome segregation errors as a cause of dna damage and structural chromosome aberrations’, *Science* **333**(6051), 1895–1898.
- Kendall, D. (1948), ‘On the generalized “birth-and-death” process’, *The annals of mathematical statistics* **19**(1), 1–15.
- Kimmel, G. J., Beck, R. J., Yu, X., Veith, T., Bakhoum, S., Altrock, P. M. and Andor, N. (2023), ‘Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction’, *PLOS Computational Biology* **19**(1), e1010815.
- Kocarnik, J. M., Compton, K., Dean, F. E., Fu, W., Gaw, B. L., Harvey, J. D., Henrikson, H. J., Lu, D., Pennini, A., Xu, R. et al. (2022), ‘Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019’, *JAMA oncology* **8**(3), 420–444.



- Kohanovski, I., Pontz, M., Vande Zande, P., Selmecki, A., Dahan, O., Pilpel, Y., Yona, A. H. and Ram, Y. (2024), 'Aneuploidy can be an evolutionary diversion on the path to adaptation', *Molecular Biology and Evolution* p. msae052.
- Lee, H.-S., Lee, N. C., Kouprina, N., Kim, J.-H., Kagansky, A., Bates, S., Trepel, J. B., Pommier, Y., Sackett, D. and Larionov, V. (2016), 'Effects of anticancer drugs on chromosome instability and new clinical implications for tumor-suppressing therapies', *Cancer research* **76**(4), 902–911.
- Levien, E., Min, J., Kondev, J. and Amir, A. (2021), 'Non-genetic variability in microbial populations: survival strategy or nuisance?', *Reports on Progress in Physics* **84**(11), 116601.
- Loeb, L. A. (2001), 'A mutator phenotype in cancer', *Cancer research* **61**(8), 3230–3239.
- Lukow, D. A., Sausville, E. L., Suri, P., Chunduri, N. K., Wieland, A., Leu, J., Smith, J. C., Girish, V., Kumar, A. A., Kendall, J. et al. (2021), 'Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies', *Developmental cell* **56**(17), 2427–2439.
- Martens, E. A., Kostadinov, R., Maley, C. C. and Hallatschek, O. (2011), 'Spatial structure increases the waiting time for cancer', *New journal of physics* **13**(11), 115014.
- Martin, G., Aguilée, R., Ramsayer, J., Kaltz, O. and Ronce, O. (2013), 'The probability of evolutionary rescue: towards a quantitative comparison between theory and evolution experiments', *Philosophical Transactions of the Royal Society B: Biological Sciences* **368**(1610), 20120088.
- Mason, J. M., Wei, X., Fletcher, G. C., Kiarash, R., Brokx, R., Hodgson, R., Beletskaya, I., Bray, M. R. and Mak, T. W. (2017), 'Functional characterization of cfi-402257, a potent and selective mps1/tyk kinase inhibitor, for the treatment of cancer', *Proceedings of the National Academy of Sciences* **114**(12), 3127–3132.
- Maynard Smith, J. and Haigh, J. (1974), 'The hitch-hiking effect of a favourable gene', *Genetics Research* **23**(1), 23–35.
- Orr, H. A. and Unckless, R. L. (2008), 'Population extinction and the genetics of adaptation', *The American Naturalist* **172**(2), 160–169.
- Orr, H. A. and Unckless, R. L. (2014), 'The population genetics of evolutionary rescue', *PLoS genetics* **10**(8), e1004551.
- Osmond, M. M., Otto, S. P. and Martin, G. (2020), 'Genetic paths to evolutionary rescue and the distribution of fitness effects along them', *Genetics* **214**(2), 493–510.
- Passerini, V., Ozeri-Galai, E., De Pagter, M. S., Donnelly, N., Schmalbrock, S., Kloosterman, W. P., Kerem, B. and Storchová, Z. (2016), 'The presence of extra chromosomes leads to genomic instability', *Nature communications* **7**(1), 10754.
- Piejko, K., Cybulska-Stopa, B., Ziętek, M., Dziura, R., Galus, Ł., Kempa-Kamińska, N., Ziółkowska, B., Rutkowska, E., Kopciński, T., Kubiowski, T. et al. (2023), 'Long-term real-world outcomes and safety of vemurafenib and vemurafenib+ cobimetinib therapy in patients with braf-mutated melanoma', *Targeted Oncology* **18**(2), 235–245.
- Pompei, S. and Cosentino Lagomarsino, M. (2023), 'A fitness trade-off explains the early fate of yeast aneuploids with chromosome gains', *Proceedings of the National Academy of Sciences* **120**(15), e2211687120.
- Replogle, J. M., Zhou, W., Amaro, A. E., McFarland, J. M., Villalobos-Ortiz, M., Ryan, J., Letai, A., Yilmaz, O., Sheltzer, J., Lippard, S. J. et al. (2020), 'Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division', *Proceedings of the National Academy of Sciences* **117**(48), 30566–30576.

- Rew, D. and Wilson, G. (2000), 'Cell production rates in human tissues and tumours and their significance. part ii: clinical data', *European Journal of Surgical Oncology (EJSO)* **26**(4), 405–417.
- Rodgers, L. T., Villano, J. L., Hartz, A. M. and Bauer, B. (2024), 'Glioblastoma standard of care: Effects on tumor evolution and reverse translation in preclinical models', *Cancers* **16**(15), 2638.
- Rutledge, S. D., Douglas, T. A., Nicholson, J. M., Vila-Casadesús, M., Kantzler, C. L., Wangsa, D., Barroso-Vilares, M., Kale, S. D., Logarinho, E. and Cimini, D. (2016), 'Selective advantage of trisomic human cells cultured in non-standard conditions', *Scientific reports* **6**(1), 22828.
- Salehi, S., Kabeer, F., Ceglia, N., Andronescu, M., Williams, M. J., Campbell, K. R., Masud, T., Wang, B., Biele, J., Brimhall, J. et al. (2021), 'Clonal fitness inferred from time-series modelling of single-cell cancer genomes', *Nature* **595**(7868), 585–590.
- Schukken, K. M. and Foijer, F. (2018), 'CIN and aneuploidy: different concepts, different consequences', *Bioessays* **40**(1), 1700147.
- Shi, Q. and King, R. W. (2005), 'Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines', *Nature* **437**(7061), 1038–1042.
- Smith, J. C. and Sheltzer, J. M. (2018), 'Systematic identification of mutations and copy number alterations associated with cancer patient prognosis', *elife* **7**, e39217.
- Spratt, J. S., Meyer, J. S. and Spratt, J. A. (1996), 'Rates of growth of human neoplasms: Part II', *Journal of Surgical Oncology* **61**(1), 68–83.
- Tanaka, M. M. and Wahl, L. M. (2022), 'Surviving environmental change: when increasing population size can increase extinction risk', *Proceedings of the Royal Society B* **289**(1976), 20220439.
- Taushanova, M. S., Milusheva, Y. I., Manov, D. A., Hadjieva, R. R. and Yordanov, A. D. (2023), 'Synchronous Occurrence of Triple-Negative Breast Cancer and Malignant Melanoma', *Journal of Medical Cases* **14**(12), 400–404.
- Tezuka, M., Hayashi, K., Kubota, K., Sekine, S., Okada, Y., Ina, H. and Irie, T. (2007), 'Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma', *Digestive diseases and sciences* **52**, 783–788.
- Thompson, S. L. and Compton, D. A. (2008), 'Examining the link between chromosomal instability and aneuploidy in human cells', *The Journal of cell biology* **180**(4), 665–672.
- Uecker, H. and Hermisson, J. (2011), 'On the fixation process of a beneficial mutation in a variable environment', *Genetics* **188**(4), 915–930.
- Uecker, H. and Hermisson, J. (2016), 'The role of recombination in evolutionary rescue', *Genetics* **202**(2), 721–732.
- Uecker, H., Otto, S. P. and Hermisson, J. (2014), 'Evolutionary rescue in structured populations', *The American Naturalist* **183**(1), E17–E35.
- Uecker, H., Setter, D. and Hermisson, J. (2015), 'Adaptive gene introgression after secondary contact', *Journal of mathematical biology* **70**, 1523–1580.
- Van Rossum, G. and Others (2007), Python programming language, in 'USENIX Annu. Tech. Conf.'.
- Varrone, M., Tavernari, D., Santamaria-Martínez, A., Walsh, L. A. and Ciriello, G. (2023), 'Cellcharter reveals spatial cell niches associated with tissue remodeling and cell plasticity', *Nature Genetics* pp. 1–11.

- Von Schuckmann, L. A., Hughes, M. C. B., Ghiasvand, R., Malt, M., Van Der Pols, J. C., Beesley, V. L., Khosrotehrani, K., Smithers, B. M. and Green, A. C. (2019), 'Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor', *JAMA Dermatology* **155**(6), 688.
- Wan, G., Nguyen, N., Liu, F., DeSimone, M. S., Leung, B. W., Rajeh, A., Collier, M. R., Choi, M. S., Amadife, M., Tang, K., Zhang, S., Phillipps, J. S., Jairath, R., Alexander, N. A., Hua, Y., Jiao, M., Chen, W., Ho, D., Duey, S., Németh, I. B., Marko-Varga, G., Valdés, J. G., Liu, D., Boland, G. M., Gusev, A., Sorger, P. K., Yu, K.-H. and Semenov, Y. R. (2022), 'Prediction of early-stage melanoma recurrence using clinical and histopathologic features', *npj Precision Oncology* **6**(1), 79.
- Wang, S., Zhang, M., Liang, D., Sun, W., Zhang, C., Jiang, M., Liu, J., Li, J., Li, C., Yang, X. et al. (2019), 'Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A medicinal chemistry perspective', *European Journal of Medicinal Chemistry* **175**, 247–268.
- Weissman, D. B., Desai, M. M., Fisher, D. S. and Feldman, M. W. (2009), 'The rate at which asexual populations cross fitness valleys', *Theoretical population biology* **75**(4), 286–300.
- Wu, B., Gokhale, C. S., van Veelen, M., Wang, L. and Traulsen, A. (2013), 'Interpretations arising from Wrightian and Malthusian fitness under strong frequency dependent selection', *Ecology and Evolution* **3**(5), 1276–1280.
- Yona, A., Frumkin, I. and Pilpel, Y. (2015), 'A Relay Race on the Evolutionary Adaptation Spectrum', *Cell* **163**(3), 549–559. Publisher: Elsevier Inc.
- Zerbib, J., Ippolito, M. R., Eliezer, Y., De Feudis, G., Reuveni, E., Kadmon, A. S., Martin, S., Viganò, S., Leor, G., Berstler, J. et al. (2023), 'Human aneuploid cells depend on the raf/mek/erk pathway for overcoming increased dna damage', *bioRxiv* pp. 2023–01.
- Zhou, Y. (2022), 'Range shifts under constant-speed and accelerated climate warming', *Bulletin of Mathematical Biology* **84**(1), 1.

	Name	Value	Units	References
$N$	Initial tumor size	$10^7 - 10^9$	cells	Del Monte (2009)
$\lambda_s$	Sensitive division rate	0.1	1/days	Bozic et al. (2013), Rew and Wilson (2000)
$\mu_s$	Sensitive death rate	0.11 – 0.17	1/days	Bozic et al. (2013)
$\lambda_a$	Aneuploid division rate*	0.06 – 0.1	1/days	-
$\mu_a$	Aneuploid death rate*	0.09	1/days	-
$\lambda_m$	Mutant division rate	0.1	1/days	Bozic et al. (2013), Rew and Wilson (2000)
$\mu_m$	Mutant death rate	0.09	1/days	Bozic et al. (2013), Carlson (2003)
$u$	Missegregation rate	$10^{-2}$	1/cell division	Lee et al. (2016)
$v$	Mutation rate	$10^{-9} - 10^{-7}$	1/cell division	Bozic et al. (2013), Loeb (2001)
$\tilde{u}$	Missegregation rate in the drug free environment*	$5 \times 10^{-4} - 2 \times 10^{-2}$	1/cell division	Shi and King (2005), Thompson and Compton (2008)
$c$	Selection coefficient against aneuploidy in the drug free environment	0.07	1/days	Lukow et al. (2021)

**Table 1: Model parameters: Melanoma.** Parameters from Bozic et al. (2013) consider patients with melanoma treated with the anti-cancer drug vemurfenib, in which resistance is conferred by trisomy in either Chr 2 or Chr 6. We have modified the parameters from Bozic et al. (2013) such that sensitive and mutant division rates are  $\lambda_s = \lambda_m = \log(2)/T \approx 0.1$  instead of their value of 0.14 where  $T$  is the doubling time in the absence of cellular death obtained from Rew and Wilson (2000). For a discussion of the different interpretations of the tumor doubling times see Avanzini and Antal (2019). Parameters marked with \* are not obtained from the literature.

## Appendices


### Appendix A Survival probability of a single lineage

To analyze evolutionary rescue in our model, we use the framework of *multi-type branching processes* (Harris, 1963, Weissman et al., 2009). In the case of cancer, where all reproduction is binary fission, these branching processes are also *birth-death processes* (Kendall, 1948). This allows us to find explicit expressions for the *survival probability*: the probability that a lineage descended from a single cell does not become extinct.


Let  $p_s$ ,  $p_a$ , and  $p_m$  be the survival probabilities of a population consisting initially of single sensitive cell, aneuploid cell, or mutant cell, respectively. The complements  $1 - p_s$ ,  $1 - p_a$ , and  $1 - p_m$

	Name	Value	Units
$\lambda_s$	Sensitive division rate	0.0845	1/days
$\mu_s$	Sensitive death rate	0.1215	1/days
$\lambda_a$	Aneuploid division rate	0.0845	1/days
$\mu_a$	Aneuploid death rate	0.076, 0.1015, 0.1115	1/days
$\lambda_m$	Mutant division rate	0.0845	1/days
$\mu_m$	Mutant death rate	0.076	1/days

**Table 2: Model parameters: Breast cancer.** The derivation of these values, described in the methods section, uses fitness estimates from Salehi et al. (2021). Parameters not listed here remain unchanged from the values provided in table 1.




**Figure 1: Model illustration.** (A) A population of cancer cells is composed of drug-sensitive, aneuploid, and mutant cells, which divide with rates  $\lambda_s$ ,  $\lambda_a$ , and  $\lambda_m$  and die at rates  $\mu_s$ ,  $\mu_a$ , and  $\mu_m$ , respectively. Sensitive cells can divide and become aneuploid at rate  $u\lambda_s$ . Both aneuploid and sensitive cells can divide and acquire a mutation with rates  $v\lambda_a$  and  $v\lambda_s$ , respectively. Color denotes the relative growth rates of the three genotypes such that  $\lambda_s - \mu_s < \lambda_a - \mu_a < \lambda_m - \mu_m$ . (B) Sensitive cells are sensitive to the drug, while mutant cells are drug-resistant. The aneuploid may be tolerant, stationary, or partially resistant.




**Figure 2: Sample trajectories of the genotype frequencies.** (A) Without aneuploidy ( $u = 0$ ), evolutionary rescue is possible through direct mutation, and in most scenarios, the tumor will become extinct due to the drug. (B) When aneuploid cells are tolerant ( $r_a < 0$ ) evolutionary rescue can occur indirectly, but direct mutation is the most likely path for evolutionary rescue. (C) When aneuploid cells are stationary ( $r_a \approx 0$ ), we observe the appearance of mutant lineages even after the sensitive population has gone extinct, thus showing that stationary aneuploidy increases the probability of evolutionary rescue. (D) When aneuploid cells are partially resistant ( $r_a > 0$ ), the tumor is rescued by the aneuploid cell population. Each plot shows 10 simulations of the number of sensitive, aneuploid, and mutant cells ( $s_t, a_t, m_t$ ) over time  $t$ . Here,  $\lambda_s = 0.1$ ,  $\lambda_m = 0.1$ ,  $\mu_s = 0.14$ ,  $\mu_a = 0.09$ ,  $\mu_m = 0.09$ ,  $\nu = 10^{-7}$ ,  $N = 10^7$ ; (A)  $u = 0$ ; (B)  $\lambda_a = 0.065$ ,  $u = 10^{-2}$ ; (C)  $\lambda_a = 0.08999$ ,  $u = 10^{-2}$ ; (D)  $\lambda_a = 0.095$ ,  $u = 10^{-2}$ .

A




B




**Figure 3: Aneuploidy facilitates the evolutionary rescue of cancer under drug treatment.** The probability of evolutionary rescue,  $p_{\text{rescue}}$ , as a function of the initial tumor size,  $N$  (eq. (1)). Dashed vertical lines show the threshold tumor size,  $N_a^*$ , above which the probability is high (eq. (3)). **(A)** Blue dashed line: without aneuploidy ( $u = 0$ ). Black line: tolerant aneuploidy ( $u = 10^{-2}$ ,  $\lambda_a = 0.0899$ ). Red line: stationary aneuploidy ( $u = 10^{-2}$ ,  $\lambda_a = 0.08999$ ). Green line: partially resistant aneuploidy ( $u = 10^{-2}$ ,  $\lambda_a = 0.095$ ). Markers and error bars for averages of simulation results with 95% confidence interval ( $p \pm 1.96\sqrt{p(1-p)/n}$  where  $p$  is the fraction of simulations in which the tumor has been rescued, and  $n = 100$  is the number of simulations). Parameters:  $\lambda_s = 0.1$ ,  $\lambda_m = 0.1$ ,  $\mu_s = 0.14$ ,  $\mu_a = 0.09$ ,  $\mu_m = 0.09$ ,  $v = 10^{-7}$ . **(B)** Comparison for melanoma and breast cancer with parameters from the literature (Tables 1 and 2). Black line: Melanoma A375. Blue line: Breast cancer TNBC-SA1035 clone H. Red line: Breast cancer TNBC-SA609 clone A. Green line: Breast cancer TNBC-SA535 clone H.

A




B




**Figure 4: Aneuploidy reduces tumor threshold size.** (A) The threshold tumor size  $N_a^*$  (eq. (3)) as a function of the aneuploid growth rate  $r_a$ . The dashed horizontal line shows  $N_m^*$  (eq. (2)), the threshold tumor size without aneuploidy ( $u = 0$ ). When aneuploid growth rate is close to or higher than zero, aneuploidy decreases the threshold tumor size, facilitating evolutionary rescue. The inset highlights the scenario when aneuploid cells are stationary. Red dots for simulations and error bars for the 95% confidence intervals obtained with bootstrap (Appendix G). Parameters:  $\lambda_s = 0.1, \lambda_m = 0.1, \mu_s = 0.14, \mu_a = 0.09, \mu_m = 0.09, u = 10^{-2}, v = 10^{-7}$ . (B) Threshold tumor size  $N_a^*$  (eq. (3)) as a function of the ratio of aneuploidy and mutation rates,  $u/v$ . Dashed horizontal line shows  $N_m^*$  (eq. (2)), the threshold tumor size without aneuploidy ( $u = 0$ ). When the aneuploidy rate is much higher than the mutation rate, aneuploidy decreases the threshold tumor size, facilitating evolutionary rescue. Blue line represents the exact formula for threshold tumor size  $N_a^*$  while the solid black line represents the approximation (eq. (3)). Red dots represent simulation results, and the error bars represent the 95% confidence intervals obtained with bootstrap (Appendix G). Parameters:  $\lambda_s = 0.1, \lambda_a = 0.0899, \lambda_m = 0.1, \mu_s = 0.14, \mu_a = 0.09, \mu_m = 0.09, v = 10^{-7}$ .





**Figure 5: Standing genetic variation facilitates the evolutionary rescue of cancer.** (A) Ratio of threshold tumor sizes for rescue by standing genetic variation and by *de novo* variation,  $\tilde{N}_a^*/N_a^*$ , when a fraction  $\frac{\tilde{u}\lambda_s}{c}$  is aneuploid at the start of treatment, as a function of the sensitive growth rate  $r_s$ . Standing genetic variation will drive adaptation to the drug if the sensitive population is rapidly declining ( $r_s \ll 0$ ) due to a stronger effect of the drug on sensitive cells. Red dots represent simulation results, and the error bars represent the 95% confidence intervals obtained with bootstrap (Appendix G). Parameters:  $\lambda_s = 0.1$ ,  $\lambda_a = 0.0899$ ,  $\lambda_m = 0.1$ ,  $\mu_a = 0.09$ ,  $\mu_m = 0.09$ ,  $\tilde{u} = 10^{-3}$ ,  $u = 10^{-2}$ ,  $v = 10^{-7}$ . (B) Ratio of threshold tumor size  $\tilde{N}_a^*$ , when a fraction  $\frac{\tilde{u}\lambda_s}{c}$  is aneuploid at the start of treatment, and  $N_a^*$  as a function of the ratio of aneuploidy rates  $\tilde{u}/u$ . *De novo* aneuploids will have a larger contribution to the appearance of drug resistance if the drug induces the appearance of aneuploid cells ( $u \gg \tilde{u}$ ). Red dots represent simulation results, and the error bars represent the 95% confidence intervals obtained with bootstrap (Appendix G). Parameters:  $\lambda_s = 0.1$ ,  $\lambda_a = 0.0899$ ,  $\lambda_m = 0.1$ ,  $\mu_s = 0.14$ ,  $\mu_a = 0.09$ ,  $\mu_m = 0.09$ ,  $\tilde{u} = 10^{-3}$ ,  $v = 10^{-7}$ .



**Figure 6: Aneuploidy extends the window of opportunity for evolutionary rescue.** (A) The probability that a successful mutant has not appeared by time  $t$ . Black line: tolerant aneuploidy ( $u > 0, \lambda_a = 0.0899$ ). Red line: stationary aneuploidy ( $u > 0, \lambda_a = 0.089999$ ). Green line: partially resistant aneuploidy ( $u > 0, \lambda_a = 0.095$ ). Blue line: no aneuploidy ( $u = 0$ ). Aneuploidy plays an important role in rescuing the tumor cell population as the sensitive population becomes extinct. Markers represent simulation results, and the error bars represent 95% confidence interval ( $p \pm 1.96\sqrt{p(1-p)/n}$  where  $p$  is the fraction of simulations in which a successful mutant has not been generated, and  $n = 100$  is the number of simulations). Parameters:  $\lambda_s = 0.1, \lambda_m = 0.1, \mu_s = 0.14, \mu_a = 0.09, \mu_m = 0.09, u = 10^{-2}, v = 10^{-7}, N = 10^7$ . (B) Probability that a mutant cancer cell population has not reached size  $N$  at time  $t$  when aneuploidy provides tolerance. Green line:  $N = 10^6$  (small tumor). Red line:  $N = 10^7$  (intermediate-sized tumor). Blue line:  $N = 10^{10}$  (large tumor). Increasing the initial tumor size guarantees that the cancer will relapse. Markers represent simulations, and the error bars represent 95% confidence interval ( $p \pm 1.96\sqrt{p(1-p)/n}$  where  $p$  is the fraction of the simulations in which the mutant population size has not reached  $N$  and  $n = 100$  is the number of simulations). Parameters:  $\lambda_s = 0.1, \lambda_a = 0.0899, \lambda_m = 0.1, \mu_s = 0.14, \mu_a = 0.09, \mu_m = 0.09, u = 10^{-2}, v = 10^{-7}$ .



**Figure 7: Tumor size decreases the mean recurrence time.** The mean time for the mutant cell population to reach size  $N$ , the initial number of cancer cells. Our inhomogeneous Poisson-process approximation (solid black line, eq. (D1)) is in agreement with simulation results (red markers with error bars for 95% CI) for intermediate size  $N$ . Simulation results converge to eq. (D4) (blue dashed line) for large values of  $N$ . The green line represents the numerical solution of eq. (D3). Parameters:  $\lambda_s = 0.1, \lambda_a = 0.0899, \lambda_m = 0.1, \mu_s = 0.14, \mu_a = 0.09, \mu_m = 0.09, u = 10^{-2}, v = 10^{-7}$ .

are the extinction probabilities, which satisfy each its respective equation (Harris, 1963),

$$\begin{aligned}
1 - p_s &= \frac{\mu_s}{\lambda_s + \mu_s + u\lambda_s + v\lambda_s} + \frac{u\lambda_s}{\lambda_s + \mu_s + u\lambda_s + v\lambda_s} (1 - p_a) (1 - p_s) + \\
&\quad \frac{\lambda_s}{\lambda_s + \mu_s + u\lambda_s + v\lambda_s} (1 - p_s)^2 + \frac{v\lambda_s}{\lambda_s + \mu_s + u\lambda_s + v\lambda_s} (1 - p_m) (1 - p_s), \\
1 - p_a &= \frac{\mu_a}{\lambda_a + \mu_a + v\lambda_a} + \frac{v\lambda_a}{\lambda_a + \mu_a + v\lambda_a} (1 - p_m) (1 - p_a) + \frac{\lambda_a}{\lambda_a + \mu_a + v\lambda_a} (1 - p_a)^2, \\
1 - p_m &= \frac{\mu_m}{\lambda_m + \mu_m} + \frac{\lambda_m}{\lambda_m + \mu_m} (1 - p_m)^2.
\end{aligned} \tag{A1}$$

The survival probabilities are given by the smallest solution for each quadratic equation (Uecker et al., 2015). Therefore we have

$$\begin{aligned}
p_s &= \frac{\lambda_s - \mu_s - u\lambda_s p_a - v\lambda_s p_m + \sqrt{(\lambda_s - \mu_s - u\lambda_s p_a - v\lambda_s p_m)^2 + 4\lambda_s^2 (u p_a + v p_m)}}{2\lambda_s}, \\
p_a &= \frac{\lambda_a - \mu_a - v\lambda_a p_m + \sqrt{(\lambda_a - \mu_a - v\lambda_a p_m)^2 + 4\lambda_a^2 v p_m}}{2\lambda_a}, \\
p_m &= \frac{\lambda_m - \mu_m}{\lambda_m}.
\end{aligned} \tag{A2}$$

Note that the equation for  $p_s$  depends on both  $p_a$  and  $p_m$ , and the equation for  $p_a$  depends on  $p_m$ . To proceed, we can plug the solution for  $p_m$  and  $p_a$  into the solution for  $p_s$ . We perform this for three different scenarios.

### Scenario 1: Aneuploid cells are partially resistant

We first assume that aneuploidy provides partial resistance to drug therapy,  $\lambda_a > \mu_a$ , and that this resistance is significant,  $(\lambda_a - \mu_a - v\lambda_a p_m)^2 > 4\lambda_a^2 v p_m$ . We thus rewrite eq. (A2) as

$$\begin{aligned}
p_s &= \frac{\lambda_s - \mu_s - u\lambda_s p_a - v\lambda_s p_m}{2\lambda_s} \left( 1 - \sqrt{1 + \frac{4\lambda_s^2 (v p_m + u p_a)}{(\lambda_s - \mu_s - u\lambda_s p_a - v\lambda_s p_m)^2}} \right), \text{ and} \\
p_a &= \frac{\lambda_a - \mu_a - v\lambda_a p_m}{2\lambda_a} \left( 1 + \sqrt{1 + \frac{4\lambda_a^2 v p_m}{(\lambda_a - \mu_a - v\lambda_a p_m)^2}} \right).
\end{aligned}$$

Using the Taylor expansion  $\sqrt{1+x} = 1 + x/2 + \mathcal{O}(x^2)$  and assuming  $u, v \ll 1$ , we obtain the following approximation for the survival probability of a population initially consisting of a single sensitive cell,

$$\begin{aligned}
p_s &\approx -\frac{v\lambda_s p_m + u\lambda_s p_a}{\lambda_s - \mu_s - u\lambda_s p_a - v\lambda_s p_m} \\
&\approx -\frac{1}{\lambda_s - \mu_s} \left[ \frac{u\lambda_s (\lambda_a - \mu_a)}{\lambda_a} + \frac{uv\lambda_s \lambda_a (\lambda_m - \mu_m)}{\lambda_m (\lambda_a - \mu_a)} + \frac{v\lambda_s (\lambda_m - \mu_m)}{\lambda_m} \right].
\end{aligned} \tag{A3}$$

Now  $uv$  is small, and if we use the fact that  $v \ll u$ , we have:

$$p_s \approx \frac{u\lambda_s}{|r_s|} \frac{r_a}{\lambda_a}. \tag{A4}$$

However, if aneuploidy is sufficiently rare such that

$$\frac{u\lambda_s r_a}{\lambda_a} < \frac{v\lambda_s r_m}{\lambda_m} \Rightarrow u\lambda_a < \frac{v\lambda_a^2 r_m}{\lambda_m} \frac{1}{r_a} < \frac{v\lambda_a^2 r_m}{\lambda_m} \frac{1}{\sqrt{4\lambda_a^2 v p_m}} \Rightarrow u\lambda_a < T^*,$$

where  $T^* = (4v\lambda_a^2 r_m / \lambda_m)^{-1/2}$  and in the second inequality we used the fact that  $r_a^2 > 4\lambda_a^2 v p_m$ . In this scenario adaptation is through direct mutation and:

$$p_s \approx \frac{v\lambda_s}{|r_s|} \frac{r_m}{\lambda_m}.$$

### Scenario 2: Aneuploid cells are tolerant.

We now assume that aneuploidy provides tolerance to drug therapy, that is, the number of aneuploid cells significantly declines over time, but at a lower rate than the number of sensitive cells,  $\lambda_s - \mu_s < \lambda_a - \mu_a < 0$ . We also assume that the decline is significant,  $(\lambda_a - \mu_a - v\lambda_a p_m)^2 > 4\lambda_a^2 v p_m$ . We rewrite eq. (A2) as

$$\begin{aligned} p_s &= \frac{\lambda_s - \mu_s - u\lambda_s p_a - v\lambda_s p_m}{2\lambda_s} \left( 1 - \sqrt{1 + \frac{4\lambda_s^2 (v p_m + u p_a)}{(\lambda_s - \mu_s - u\lambda_s p_a - v\lambda_s p_m)^2}} \right), \\ p_a &= \frac{\lambda_a - \mu_a - v\lambda_a p_m}{2\lambda_a} \left( 1 - \sqrt{1 + \frac{4\lambda_a^2 v p_m}{(\lambda_a - \mu_a - v\lambda_a p_m)^2}} \right). \end{aligned} \quad (\text{A5})$$

Since  $u, v \ll 1$ , the term in the root can be approximated using a Taylor expansion. So, substituting the expressions for  $p_a$  and  $p_m$ , we have

$$\begin{aligned} p_s &\approx -\frac{v\lambda_s p_m + u\lambda_s p_a}{\lambda_s - \mu_s - u\lambda_s p_a - v\lambda_s p_m} \\ &\approx \frac{1}{\lambda_s - \mu_s - u\lambda_s p_a - v\lambda_s p_m} \left[ \frac{uv\lambda_s \lambda_a (\lambda_m - \mu_m)}{\lambda_m (\lambda_a - \mu_a - v\lambda_a)} - \frac{v\lambda_s (\lambda_m - \mu_m)}{\lambda_m} \right] \\ &\approx \frac{v\lambda_s (\lambda_m - \mu_m)}{\lambda_m (\lambda_s - \mu_s)} \left[ \frac{u\lambda_a}{(\lambda_a - \mu_a)} - 1 \right] \\ &= \frac{v\lambda_s r_m}{\lambda_m |r_s|} \left( \frac{u\lambda_a}{|r_a|} + 1 \right). \end{aligned} \quad (\text{A6})$$

If we assume that aneuploidy is not rare ( $u\lambda_a > |r_a|$ ) then we have:

$$p_s \approx \frac{u\lambda_s}{|r_s|} \frac{v\lambda_a}{|r_a|} \frac{r_m}{\lambda_m}. \quad (\text{A7})$$

### Scenario 3: Aneuploid cells are stationary

We now assume that the growth rate of aneuploid cells is close to zero (either positive or negative), such that  $(r_a - v\lambda_a p_m)^2 \ll 4\lambda_a^2 v p_m$ . We rewrite eq. (A2) as

$$p_a = \frac{\lambda_a - \mu_a - v\lambda_a p_m + 2\sqrt{\lambda_a^2 v p_m} \left( 1 + \frac{(\lambda_a - \mu_a - v\lambda_a p_m)^2}{4\lambda_a^2 v p_m} \right)^{\frac{1}{2}}}{2\lambda_a}. \quad (\text{A8})$$

Using a following Taylor series expansion for small  $(\lambda_a - \mu_a - v\lambda_a p_m)^2 / 4\lambda_a^2 v p_m$ ,

$$\left(1 + \frac{(\lambda_a - \mu_a - v\lambda_a p_m)^2}{4\lambda_a^2 v p_m}\right)^{\frac{1}{2}} = 1 + \frac{(\lambda_a - \mu_a - v\lambda_a p_m)^2}{8\lambda_a^2 v p_m} + \dots,$$

we obtain the approximation

$$\begin{aligned} p_a &\approx \frac{\lambda_a - \mu_a - v\lambda_a p_m + 2\sqrt{\lambda_a^2 v p_m} \left[1 + \frac{(\lambda_a - \mu_a - v\lambda_a p_m)^2}{8\lambda_a^2 v p_m}\right]}{2\lambda_a} \\ &= \frac{\lambda_a - \mu_a - v\lambda_a p_m + 2\sqrt{\lambda_a^2 v p_m} + \frac{(\lambda_a - \mu_a - v\lambda_a p_m)^2}{4\sqrt{\lambda_a^2 v p_m}}}{2\lambda_a} \\ &= \frac{(\lambda_a - \mu_a - v\lambda_a p_m + 2\sqrt{\lambda_a^2 v p_m})^2 + 4\lambda_a^2 v p_m}{8\lambda_a \sqrt{\lambda_a^2 v p_m}} \\ &= \frac{4\lambda_a^2 v p_m + 4\lambda_a^2 v p_m \left(1 + \frac{\lambda_a - \mu_a - v\lambda_a p_m}{2\sqrt{\lambda_a^2 v p_m}}\right)^2}{8\lambda_a \sqrt{\lambda_a^2 v p_m}} \\ &= \frac{1}{2\lambda_a} \left(\lambda_a - \mu_a - v\lambda_a p_m + 2\sqrt{\lambda_a^2 v p_m}\right). \end{aligned} \tag{A9}$$

Plugging this in eq. (A3), the survival probability of a population starting from one sensitive cell is

$$\begin{aligned} p_s &\approx -\frac{1}{\lambda_s - \mu_s - u\lambda_s p_a - v\lambda_s p_m} \left[ v\lambda_s \frac{\lambda_m - \mu_m}{\lambda_m} + \frac{u\lambda_s}{2\lambda_a} \left(\lambda_a - \mu_a - v\lambda_a p_m + 2\sqrt{\lambda_a^2 v p_m}\right) \right] \\ &= -\frac{1}{\lambda_s - \mu_s - u\lambda_s p_a - v\lambda_s p_m} \left[ v\lambda_s \frac{\lambda_m - \mu_m}{\lambda_m} + \frac{u\lambda_s}{2\lambda_a} (\lambda_a - \mu_a - v\lambda_a p_m) + u\lambda_s \sqrt{\frac{v(\lambda_m - \mu_m)}{\lambda_m}} \right] \\ &\approx -\frac{1}{r_s} \left[ v\lambda_s \frac{r_m}{\lambda_m} + \frac{u\lambda_s (r_a - v\lambda_a p_m)}{2\lambda_a} + u\lambda_s \sqrt{\frac{v r_m}{\lambda_m}} \right]. \end{aligned} \tag{A10}$$

Using the fact that

$$(r_a - v\lambda_a p_m)^2 \ll 4\lambda_a^2 v p_m \Rightarrow \frac{r_a - v\lambda_a p_m}{2\lambda_a} \ll \sqrt{\frac{v\lambda_a r_m}{\lambda_m}},$$

and  $v \ll u$  we obtain:

$$p_s \approx \frac{u\lambda_s}{|r_s|} \sqrt{\frac{v\lambda_a r_m}{\lambda_m}}. \tag{A11}$$

## Appendix B Evolutionary rescue probability

Using the fact that  $r_a - v\lambda_a p_m \approx r_a$  we write the condition  $(r_a - v\lambda_a p_m)^2 \ll 4\lambda_a^2 v p_m$  as:

$$r_a^2 \ll 4\lambda_a^2 v p_m \Rightarrow -1 \ll r_a T^* \ll 1,$$

where  $T^* = (4v\lambda_a^2 r_m / \lambda_m)^{-1/2}$ . Substituting eqs. (A4), (A7) and (A11) into eq. (1), the evolutionary rescue probability can be approximated by

$$p_{\text{rescue}} \approx \begin{cases} 1 - \exp \left[ -\frac{u\lambda_a}{|r_s|} \frac{v\lambda_s}{|r_a|} \frac{r_m}{\lambda_m} N \right], & r_a T^* \ll -1, \\ 1 - \exp \left[ -\frac{u\lambda_s}{|r_s|} \sqrt{\frac{v\lambda_a r_m}{\lambda_m}} N \right], & -1 \ll r_a T^* \ll 1, \\ 1 - \exp \left[ -\frac{u\lambda_s}{|r_s|} \frac{r_a}{\lambda_a} N \right], & 1 \ll r_a T^*. \end{cases} \quad (\text{B1})$$

## Appendix C Evolutionary rescue time

We first calculate the expected time for the appearance of the first mutant that rescues the cell population. This can occur either through the evolutionary trajectory *sensitive*  $\rightarrow$  *mutant* or through the trajectory *sensitive*  $\rightarrow$  *aneuploid*  $\rightarrow$  *mutant*. We start with the former.

Assuming no aneuploidy ( $u = 0$ ), we define  $T_m$  to be the time at which the first mutant cell appears that will avoid extinction and will therefore rescue the population. Note that if extinction occurs, that is the frequency of mutants after a long time is zero,  $m_\infty = 0$ , then it is implied that  $T_m = \infty$ , and vice versa if  $T_m < \infty$  then  $m_\infty > 0$ .

The number of successful mutants generated until time  $t$  can be approximated by an inhomogeneous Poisson process with rate  $R_m(t) = v\lambda_s p_m s_t$ , where  $s_t = Ne^{r_s t}$  is the number of sensitive cells at time  $t$ . Note that

$$\int_0^t R_m(z) dz = v\lambda_s p_m N \frac{\exp[r_s t] - 1}{r_s} \approx v\lambda_s p_m N t, \quad (\text{C1})$$

by integrating the exponential and because  $\frac{1}{r_s} (\exp[r_s t] - 1) = t + O(r_s t^2)$ . The probability density function of  $T_m$  is thus  $R_m(t) \exp \left( -\int_0^t R_m(z) dz \right)$  (Allen, 2010). Therefore, the probability density function of the conditional random variable  $(T_m \mid T_m < \infty)$  is  $f_m(t) = R_m(t) \exp \left( -\int_0^t R_m(z) dz \right) / p_{\text{rescue}}$ .

We are interested in the mean conditional time,  $\tau_m = \mathbb{E}[T_m \mid T_m < \infty]$ , which is given by

$$\tau_m = \int_0^\infty t f_m(t) dt = \frac{\int_0^\infty t R_m(t) \exp \left( -\int_0^t R_m(z) dz \right) dt}{p_{\text{rescue}}}, \quad (\text{C2})$$

Therefore, plugging eqs. (1) and (C1) in eq. (C2),

$$\tau_m = \int_0^\infty t v\lambda_s N e^{r_s t} \frac{e^{-v\lambda_s N p_m \frac{e^{r_s t} - 1}{r_s}}}{1 - (1 - p_s)^N} dt \approx \int_0^\infty t v\lambda_s N e^{r_s t} \frac{e^{-v\lambda_s N p_m t}}{1 - e^{-N p_s}} dt. \quad (\text{C3})$$

Figure S2B shows the agreement between this approximation and simulation results.

Assuming aneuploidy is possible ( $u > 0$ ), we define  $T_a$  to be the time at which the first mutant cell appears that will rescue the population. We are interested in the mean conditional time,  $\tau_a = \mathbb{E}[T_a \mid T_a < \infty]$ .

When  $Nu\lambda_s/|r_s| \gg 1$  the aneuploid frequency dynamics is roughly deterministic and therefore can be approximated by

$$a_t \approx \frac{Nu\lambda_s}{r_s - r_a} (e^{r_s t} - e^{r_a t}). \quad (\text{C4})$$

As a result, the number of successful mutants created by direct mutation and via aneuploidy can be approximated by inhomogeneous Poisson processes with the rates

$$n_1(t) = v\lambda_a p_m a_t,$$

$$r_2(t) = v\lambda_s p_m s_t,$$

and the expected number of successful mutants created by direct mutation and via aneuploidy until time  $t$  is given by:

$$M_a(t) = v\lambda_a p_m \int_0^t a_z dz = \frac{uv\lambda_s \lambda_a N p_m}{r_s - r_a} \left( \frac{e^{r_s t} - 1}{r_s} - \frac{e^{r_a t} - 1}{r_a} \right), \quad (C5)$$

$$M_m(t) = v\lambda_s p_m \int_0^t s_z dz = v\lambda_s N p_m \frac{e^{r_s t} - 1}{r_s}. \quad (C6)$$

For large initial population sizes we assume that the two processes are independent and as a result, they can be merged into a single Poisson process with rate  $R_a(t) = (n_1 + r_2)(t)$ . The mean time to the appearance of the first rescue mutant is

$$\begin{aligned} \tau_a &= \frac{\int_0^\infty t R_a(t) \exp\left(-\int_0^t R_a(z) dz\right) dt}{p_{\text{rescue}}} \\ &= \int_0^\infty t (v\lambda_a p_m a_t + v\lambda_s p_m s_t) \frac{\exp\left[-\frac{uv\lambda_s \lambda_a N p_m}{r_s - r_a} \left(\frac{e^{r_s t} - 1}{r_s} - \frac{e^{r_a t} - 1}{r_a}\right) - v\lambda_s N p_m \frac{e^{r_s t} - 1}{r_s}\right]}{1 - e^{-N p_s}} dt, \end{aligned} \quad (C7)$$

which we plot in Figure S2A as a function of the initial population size,  $N$ .

Paradoxically, we observe from Figure S2 that the mean time of a rescue mutation to appear is significantly shorter for the scenario when  $u = 0$  when compared to the scenario  $u > 0$ , however this can be explained by the fact this mean time is conditioned on evolutionary rescue and, as a result, aneuploidy increase the *window of opportunity* in which a rescue mutation could appear thus increasing the mean time as well (Figure 2).

Let  $N_a^*$  and  $N_m^*$  be the threshold population size above which evolutionary rescue through aneuploidy or direct mutation, respectively, is likely. The mean time  $\tau_a$  can be written as:

$$\begin{aligned} \tau_a &= \int_0^\infty t f(t) dt = \int_0^\infty t \frac{d}{dt} F(t) dt = - \int_0^\infty t \frac{d}{dt} S(t) dt \\ &= -[tS(t)]_0^\infty + \int_0^\infty S(t) dt \\ &= \int_0^\infty S(t) dt, \end{aligned}$$

where  $f(t)$ ,  $F(t)$  and  $S(t)$  are the probability density function, cumulative distribution function and survival function. In our case,  $S(t) = \exp\left(-\int_0^t R_a(z) dz\right)$ . Additionally, for  $N \gg N_m^*$  we have  $1 - e^{-N p_s} \approx 1$  and, as a result, we have:

$$\tau_a = \int_0^\infty e^{-\int_0^t R_a(z) dz} dt = \int_0^\infty \exp\left[-\frac{uv\lambda_s \lambda_a N p_m}{r_s - r_a} \left(\frac{e^{r_s t} - 1}{r_s} - \frac{e^{r_a t} - 1}{r_a}\right) - v\lambda_s N p_m \frac{e^{r_s t} - 1}{r_s}\right] dt,$$

and we use the following Taylor series expansions:

$$\frac{e^{r_s t} - 1}{r_s} = \frac{1 + r_s t + O(t^2) - 1}{r_s} = t + O(t^2).$$



$$\frac{e^{r_a t} - 1}{r_a} = \frac{1 + r_a t + O(t^2) - 1}{r_a} = t + O(t^2),$$

to obtain a simpler approximation for  $\tau_a$ :

$$\tau_a \approx \int_0^\infty e^{-v\lambda_s N p_m t} dt = \frac{1}{v\lambda_s N p_m}. \quad (\text{C8})$$

If  $N \ll N_a^*$  then the probability distribution of evolutionary rescue time is skewed toward small values (i.e. evolutionary rescue occurs conditioned on it happening). As a result, we have:

$$\begin{aligned} \frac{e^{r_s t} - 1}{r_s} &= \frac{1 + r_s t + O((r_s t)^2) - 1}{r_s} = t + O(r_s t^2) \\ \frac{e^{r_a t} - 1}{r_a} &= \frac{1 + r_a t + O((r_a t)^2) - 1}{r_a} = t + O(r_a t^2) \end{aligned}$$

We observe that the first term in the exponential in eq. (C7) can be approximated to be zero and the second term as  $-v\lambda_s N p_m t$  where  $t \ll 1$ . As a result, we can approximate:

$$\exp \left[ -\frac{uv\lambda_s \lambda_a N p_m}{r_s - r_a} \left( \frac{e^{r_s t} - 1}{r_s} - \frac{e^{r_a t} - 1}{r_a} \right) - v\lambda_s N p_m \frac{e^{r_s t} - 1}{r_s} \right] \sim 1$$

Additionally, since  $N \ll N_a^* \ll N_m^*$ , evolutionary rescue is more likely to occur through the trajectory *sensitive*  $\rightarrow$  *aneuploid*  $\rightarrow$  *mutant*. As a result, we can write Equation (C7) as:

$$\begin{aligned} \tau_a &\approx \frac{\int_0^\infty t v \lambda_a p_m a_t dt}{1 - e^{-N p_s}} \approx \frac{uv \lambda_a \lambda_s p_m |r_s + r_a|}{p_s r_a^2 r_s^2} \\ &= \frac{1}{|r_s|} + \frac{1}{|r_a|}, \end{aligned} \quad (\text{C9})$$

where in the last line we used the fact that  $1/p_s = N_a^*$  and Equation (3).

If a fraction  $f$  of the cancer cells are aneuploid when the drug is administered then the expected number of successful mutants generated until time  $t$  is given by:

$$\begin{aligned} n_1^f(t) &= v \lambda_a p_m \int_0^t a_z dz = (1 - f) \frac{uv \lambda_s \lambda_a N p_m}{r_s - r_a} \left( \frac{e^{r_s t} - 1}{r_s} - \frac{e^{r_a t} - 1}{r_a} \right) + f v \lambda_a N p_m \frac{e^{r_a t} - 1}{r_a}, \\ r_2^f(t) &= v \lambda_s p_m \int_0^t s_z dz = (1 - f) v \lambda_s N p_m \frac{e^{r_s t} - 1}{r_s}, \end{aligned}$$

and the mean evolutionary rescue time is given by:

$$\tilde{\tau}_a = \frac{\int_0^\infty t R_a^f(t) \exp \left( -\int_0^t R_a^f(z) dz \right) dt}{p_{\text{rescue}}}, \quad (\text{C10})$$

where  $R_a^f(t) = n_1^f(t) + r_2^f(t)$  and  $p_{\text{rescue}} = 1 - \exp \left[ - (1 - f) p_s N - f p_a N \right]$ . We plot our approximation in Figure S9 together with simulated data.

## Appendix D Recurrence time

In the following, we assume aneuploid cells are tolerant ( $r_a T^* \ll -1$ ) and frequent enough to affect the evolution of drug resistance ( $u\lambda_a \gg \max(-r_a, 1/T^*)$ ). We define the proliferation time  $\tau_a^p$  to be the expected time for the number of resistant cells to grow to the initial tumor size  $N$ . The number of rescue lineages generated by the sensitive population is given by eq. (C5) (see Figure S3),

$$n_1(\infty) = \frac{uv\lambda_s\lambda_a N p_m}{|r_s||r_a|} + \frac{v\lambda_s N p_m}{|r_s|} = \frac{N}{N_a^*} + \frac{N}{N_m^*}.$$

We use eqs. (2) and (3) to write  $N_a^* = \frac{|r_s||r_a|}{uv\lambda_s\lambda_a p_m}$  and  $N_m^* = \frac{|r_s|}{v\lambda_s p_m}$ .

We distinguish between small, intermediate, or large tumors. In small ( $N \ll N_a^* \ll N_m^*$ ) tumors, we have at most one lineage that rescues the cancer cell population. As a result, the recurrence time is given by (Avanzini and Antal, 2019)

$$\tau_a^r \approx \tau_a + \frac{\log(p_m N)}{r_m}. \quad (D1)$$

The factor  $p_m$  in the second term of eq. (D1) occurs because the lineage is conditioned to survive stochastic extinction and the time to reach  $N$  is shorter compared to the scenario where the lineage is not conditioned to survive stochastic extinction (Maynard Smith and Haigh, 1974, Orr and Unckless, 2014). Therefore, in small tumors, we can substitute eq. (C9) for  $\tau_a$  in eq. (D1) to get (blue line in Figure S7)

$$\tau_a^r \approx 1/|r_a| + \log(p_m N)/r_m.$$

In intermediate tumors,  $N_a^* \ll N \ll N_m^*$ , the sensitive cell population generates a number of rescue lineages in a short period of time after  $\tau_a$ . The time it takes the rescue lineages to reach the initial population size  $N$  is small compared to the time it took the lineages to appear. Therefore, the mean recurrence time can be approximated by substituting eq. (C7) for  $\tau_a$  in eq. (D1) (black line in Figure S7).

In large tumors,  $N_m^* \ll N$ , the sensitive population produces a large number of rescue lineages in a short period of time. As a result, the recurrence time is obtained by solving the following system of ordinary differential equations (ODEs),

$$\begin{aligned} \frac{ds}{dt} &= r_s s, \\ \frac{da}{dt} &= r_a a + u\lambda_s s, \\ \frac{dm}{dt} &= r_m m + v\lambda_a a + v\lambda_s s. \end{aligned} \quad (D2)$$

Solving the system of ODEs for initial condition  $(s(0), a(0), m(0)) = (N, 0, 0)$  we obtain:

$$m(t) = \frac{Nuv\lambda_a\lambda_s}{r_a - r_s} \left[ \frac{e^{r_m t} - e^{r_a t}}{r_m - r_a} - \frac{e^{r_m t} - e^{r_s t}}{r_m - r_s} \right] + Nv\lambda_s \frac{e^{r_m t} - e^{r_s t}}{r_m - r_s}.$$

We obtain  $\tau_a^r$  by solving the above equation for time  $t = \tau_a^r$  at which the number of mutant cells reaches  $N$ , that is, we solve  $m(\tau_a^r) = N$ ,

$$1 = \frac{uv\lambda_a\lambda_s}{r_a - r_s} \left[ \frac{e^{r_m \tau_a^r} - e^{r_a \tau_a^r}}{r_m - r_a} - \frac{e^{r_m \tau_a^r} - e^{r_s \tau_a^r}}{r_m - r_s} \right] + v\lambda_s \frac{e^{r_m \tau_a^r} - e^{r_s \tau_a^r}}{r_m - r_s}. \quad (D3)$$

Equation (D3) is a transcendental equation which cannot be solved exactly but we can obtain an approximation by noting that the tumor size  $N$  is large, and because the sensitive and aneuploid cells have negative growth rates, almost all of the growth needed to rebound to size  $N$  will be by mutant cells. Mathematically, this corresponds to  $e^{r_m \tau_a^r}$  being much larger than the other exponential terms,  $e^{r_s \tau_a^r}$  and  $e^{r_a \tau_a^r}$ . Equation (D3) can then be rewritten as

$$1 \approx \frac{v\lambda_s e^{r_m \tau_a^r}}{r_m - r_s} \left( \frac{u\lambda_a}{r_m - r_a} + 1 \right).$$

Assuming that rate of aneuploidy is not so high that it overwhelms the aneuploids' growth disadvantage relative to the mutants ( $u\lambda_a \ll r_m - r_a$ ), we can neglect the first term in parentheses above, yielding (green line in Figure S7)

$$\tau_a^r \approx \frac{1}{r_m} \log \left( \frac{r_m - r_s}{v\lambda_s} \right). \quad (\text{D4})$$

We emphasize that in this case the population is large enough to produce mutants without needing to pass through aneuploidy ( $N \gg N_m^*$ ), and so the terms arising from the evolutionary trajectory *sensitive*  $\rightarrow$  *aneuploid*  $\rightarrow$  *mutant* do not contribute to the above approximation.

Additionally, we note that if we are interested in the time until the tumor reaches a detectable size  $M$  then our above analysis is valid but in eq. (D1) we change

$$\tau_a^{r,M} \approx \tau_a + \frac{\log(p_m M)}{r_m}, \quad (\text{D5})$$

and eq. (D4) becomes

$$\tau_a^{r,M} \approx \frac{1}{r_m} \log \left( \frac{M(r_m - r_s)}{v\lambda_s N} \right), \quad (\text{D6})$$

which we plot in Figure S8 and observe that our approximations are in agreement with simulations.

## Appendix E Distribution of evolutionary rescue time

The probability that a successful mutant has been generated by time  $t$  is given by:

$$\begin{aligned} P(\text{rescue}, t) &= P(T_a < t) \\ &= 1 - \exp \left\{ - \left[ n_1(t) + r_2(t) \right] \right\} \\ &= 1 - \exp \left\{ - \left[ \frac{uv\lambda_s \lambda_a N p_m}{r_s - r_a} \left( \frac{e^{r_s t} - 1}{r_s} - \frac{e^{r_a t} - 1}{r_a} \right) + v\lambda_s N p_m \frac{e^{r_s t} - 1}{r_s} \right] \right\}, \end{aligned}$$

where  $T_a$  is the time at which the first mutant cell appears that will avoid extinction and which was defined in appendix C.

As a result, the probability that a successful mutant has not been generated by time  $t$  is:

$$1 - P(\text{rescue}, t) = \exp \left\{ - \left[ \frac{uv\lambda_s \lambda_a N p_m}{r_s - r_a} \left( \frac{e^{r_s t} - 1}{r_s} - \frac{e^{r_a t} - 1}{r_a} \right) + v\lambda_s N p_m \frac{e^{r_s t} - 1}{r_s} \right] \right\}. \quad (\text{E1})$$

## Appendix F Distribution of recurrence time

The probability distribution of the time that a lineage, consisting initially of a single cell, will reach size  $N$  as time  $t$  is given by the Gumbel distribution  $\text{Gumb}_{\max} \left( \frac{\log N p_m}{r_m}, \frac{1}{r_m} \right)$  (Avanzini and Antal, 2019) with probability density function:

$$G(t) = e^{-p_m N e^{-r_m t}}.$$

A mutant lineage initiated at time  $s$ , through aneuploidy, at rate  $v\lambda_a p_m a_s$  reaches size  $N$  before time  $t$  with probability  $G(t - s)$  where  $s \leq t$ . As a result, the number of successful mutant lineages which reach size  $N$  by time  $t$  can be approximated by inhomogeneous Poisson random variable with rate:

$$r(t) = v\lambda_a p_m \int_0^t a_s G(t - s) ds$$

where  $a_s$  is aneuploid population size at time  $s$  defined in eq. (C4). The proliferation time is defined as the first time the size of all lineages reaches  $N$ . When  $N \ll |r_s||r_a|/uv\lambda_s\lambda_a p_m$  there is at most a single mutant lineage that will survive and reach size  $N$  (Figure S3) and the probability that the size of that lineage has not reached  $N$  by time  $t$  is given by:

$$\begin{aligned} P(m_t \leq N) &= \exp[-r(t)] \\ &= \exp\left[-\frac{Nuv\lambda_s\lambda_a p_m}{r_s - r_a} \int_0^t [e^{r_s x} - e^{r_a x}] e^{-p_m N e^{-r_m(t-x)}} dx\right]. \end{aligned} \quad (F1)$$

When  $N \gg |r_s||r_a|/uv\lambda_s\lambda_a p_m$  the dynamics of the cancer cell populations is deterministic and approximated by the system of ODEs shown in eq. (D2). As a result, the size of the mutant cell population will always be below  $N$  until time  $\tau_a^r$  and will always be greater after:

$$P(m_t \leq N) = 1 - H(t - \tau_a^r), \quad (F2)$$

where  $H(x)$  is the Heaviside function:

$$H(x) = \begin{cases} 0, & x < 0, \\ 1, & x \geq 0. \end{cases}$$

We plot eq. (F1) and eq. (F2) in Figure 6B and compare with stochastic simulations and observe that our approximations are in agreement.

We observe that for  $N = 10^7$  our formula overestimates the probability that the mutant population will be smaller than  $N$  at time  $t$ . This can be explained by the fact that  $N = 10^7$  is an intermediary scenario where the sensitive population produces a number of rescue lineages that is greater than one but still sufficiently small such that stochasticity plays an important role in the population dynamics. As a result, the number of mutant cancer cells will reach  $N$  faster than the scenario with a single mutant lineage. Additionally, we observe from Figure 6B that the probability of the mutant cell population reaching size  $N$  is approximately zero before time  $\tau_a^r$  which is the recurrence time for the deterministic scenario. This can be explained as follows: in the deterministic scenario there is a sufficient number of lineages produced such that there exists a lineage where each descendant will only reproduce and not die; the time it takes for this lineage to reach  $N$  is the lower bound for the time of all other lineages to reach  $N$  and this time cannot be smaller than  $\tau_a^r$  by definition. Given that for small values of  $N$  we expect that at most a single lineage will rescue the tumor, this lineage cannot reach  $N$  before  $\tau_a^r$  for the deterministic scenario eq. (D4).

From eq. (F1) we obtain the distribution of the recurrence time conditional of evolutionary rescue:

$$f(t) = \frac{d}{dt} \left[ \frac{P(m_t \geq N)}{p_{\text{rescue}}} \right] = r'(t) \frac{\exp[-r(t)]}{p_{\text{rescue}}}, \quad (F3)$$

which we plot in Figure S4 and compare with simulations. We note that in the scenario  $N \gg |r_s||r_a|/uv\lambda_s\lambda_a p_m$  the distribution becomes the Dirac  $\delta$ -function (Barton, 1989).

## Appendix G Bootstrap

For the mean times the 95% confidence interval is obtained through bootstrapping in the following steps: (1) we simulate  $T$  100 times; (2) we sample with replacement which we store in  $T'$ ; (3) for each element of this sample we obtain  $\tau = \mathbb{E}[T']$ ; (4) we repeat steps (2)-(3) 100 times to obtain  $\tau$  and we select the upper and lower limits such that 95% of the values of  $\tau$  lie in the interval given by the bounds.

For the threshold tumor sizes the 95% confidence interval is obtained through bootstrapping in the following steps: (1) we simulate  $p_{\text{rescue}}$  100 times; (2) we sample with replacement which we store in  $S$ ; (3) for each element of this sample we obtain  $N_a^* = 1/p_s$  using  $p_s = -1/N_e \log(1 - \bar{S})$  where  $\bar{S}$  is the mean of  $S$  and  $N_e$  is an arbitrary value of the initial population size we selected in order to calculate  $p_{\text{rescue}}$ ; (4) we repeat steps (2)-(3) 100 times to obtain  $N_a^*$  and we select the upper and lower limits such that 95% of the values of  $N_a^*$  lie in the interval given by the bounds.

For the ratio of the threshold tumor sizes the 95% confidence interval is obtained through bootstrapping in the following steps: (1) we simulate  $p_{\text{rescue}}$  100 times for both the scenario when  $f = \tilde{u}\lambda_s/c$  and  $f = 0$ ; (2) we sample with replacement which we store in  $S_f$  and  $S_0$ ; (4) for each element of  $S_0$  we obtain  $N_a^* = 1/p_s$  using  $p_s = -1/N_e \log(1 - \bar{S})$  where  $\bar{S}$  is the mean of  $S_0$  and  $N_e$  is an arbitrary value of the initial population size we selected in order to calculate  $p_{\text{rescue}}$ ; (5) for each element of  $S_f$  we obtain  $\tilde{N}_a^* = 1/p_a$  using  $p_a = -f/N_e \log(1 - \bar{S})$  where  $\bar{S}_f$  is the mean of  $S_f$  and  $N_e$  is an arbitrary value of the initial population size we selected in order to calculate  $p_{\text{rescue}}$ ; (6) we repeat steps (2)-(5) 100 times to obtain  $\tilde{N}_a^*/N_a^*$  and we select the upper and lower limits such that 95% of the values of  $\tilde{N}_a^*/N_a^*$  lie in the interval given by the bounds.

## Appendix H Aneuploidy-induced mutation rate

The mutation rate may be increased in aneuploid cells. To account for an increased mutation rate in cells with the aneuploidy that provides a fitness advantage in the presence of a drug, we extend our model such that sensitive cells mutate with rate  $v_s$  and aneuploid cells mutate with rate  $v_a$ . Note that sensitive cells include those cells with any other aneuploidy, including those that may cause an increased mutation rate, and therefore those cases are already covered by the model presented in the main text. We then calculate the survival probabilities  $p_s$ ,  $p_a$  and  $p_m$  as in Appendix A,

$$\begin{aligned}
 1 - p_s &= \frac{\mu_s}{\lambda_s + \mu_s + u\lambda_s + v_s\lambda_s} + \frac{u\lambda_s}{\lambda_s + \mu_s + u\lambda_s + v_s\lambda_s} (1 - p_a) (1 - p_s) + \\
 &\quad \frac{\lambda_s}{\lambda_s + \mu_s + u\lambda_s + v_s\lambda_s} (1 - p_s)^2 + \frac{v_s\lambda_s}{\lambda_s + \mu_s + u\lambda_s + v_s\lambda_s} (1 - p_m) (1 - p_s), \\
 1 - p_a &= \frac{\mu_a}{\lambda_a + \mu_a + v_a\lambda_a} + \frac{v_a\lambda_a}{\lambda_a + \mu_a + v_a\lambda_a} (1 - p_m) (1 - p_a) + \frac{\lambda_a}{\lambda_a + \mu_a + v_a\lambda_a} (1 - p_a)^2, \\
 1 - p_m &= \frac{\mu_m}{\lambda_m + \mu_m} + \frac{\lambda_m}{\lambda_m + \mu_m} (1 - p_m)^2.
 \end{aligned} \tag{H1}$$

Solving the above equations we obtain

$$\begin{aligned}
p_s &= \frac{\lambda_s - \mu_s - u\lambda_s p_a - v_s \lambda_s p_m + \sqrt{(\lambda_s - \mu_s - u\lambda_s p_a - v_s \lambda_s p_m)^2 + 4\lambda_s^2 (u p_a + v_s p_m)}}{2\lambda_s}, \\
p_a &= \frac{\lambda_a - \mu_a - v_a \lambda_a p_m + \sqrt{(\lambda_a - \mu_a - v_a \lambda_a p_m)^2 + 4\lambda_a^2 v_a p_m}}{2\lambda_a}, \\
p_m &= \frac{\lambda_m - \mu_m}{\lambda_m}.
\end{aligned} \tag{H2}$$

The threshold population size can be written as

$$N_a^* \approx \frac{|r_s|}{u\lambda_s} \cdot \begin{cases} \frac{|r_a|}{v_a \lambda_a} \frac{\lambda_m}{r_m}, & r_a T^* \ll -1 \text{ (tolerant aneuploids),} \\ 2\lambda_a T^*, & -1 \ll r_a T^* \ll 1 \text{ (stationary aneuploids),} \\ \frac{\lambda_a}{r_a}, & r_a T^* \gg 1 \text{ (resistant aneuploids),} \end{cases} \tag{H3}$$


where  $T^* = (4v_a \lambda_a^2 p_m)^{-\frac{1}{2}}$ . This is the same as in eq. (3) except with  $v_a$  instead of  $v$ .

The probability of evolutionary rescue is


$$p_{\text{rescue}} = 1 - (1 - p_s)^N \approx 1 - e^{-N p_s} = 1 - e^{-N/N_a^*}, \tag{H4}$$

which we plot in Figure S10 for multiple values of  $v_a$ . We note that when  $v_a = 10^{-5}$ , we are in the case of stationary aneuploidy (i.e.,  $r_a T^* \approx -0.55$ ).

## Supplementary Figures




**Figure S1: Density dependent growth does not affect the accuracy of our model.** Comparison of results of simulations with density-dependent growth (red markers with 95% CI) and the approximation formula (black line, eq. (3) in eq. (1)) with maximum carrying capacity  $K = 10^8$  and effective carrying capacity  $K_e = Kr_a/\lambda_a \approx 10^6$ . The error bars represent 95% confidence interval of the form  $p \pm 1.96\sqrt{p(1-p)/n}$  where  $p$  is the fraction of simulations in which the tumor has adapted to the stress and  $n = 100$  is the number of simulations. Parameters:  $\lambda_s = 0.1, \lambda_a = 0.0901, \lambda_m = 0.1, \mu_s = 0.14, \mu_a = 0.09, \mu_m = 0.09, u = 10^{-2}, v = 10^{-7}, K = 10^8$ .



**Figure S2: Evolutionary rescue time.** Shown is the mean time for appearance of a resistance mutation that leads to evolutionary rescue (A) with aneuploidy ( $u > 0$ ) and (B) without aneuploidy ( $u = 0$ ). Our inhomogeneous Poisson-process approximations (solid black lines, right: eq. (C2), left: eq. (C7)) are in agreement with simulation results (red markers with 95% quantile intervals obtained with bootstrapping, see Appendix G). Parameters:  $\lambda_s = 0.1$ ,  $\lambda_a = 0.0899$ ,  $\lambda_m = 0.1$ ,  $\mu_s = 0.14$ ,  $\mu_a = 0.09$ ,  $\mu_m = 0.09$ ,  $u = 10^{-2}$ ,  $v = 10^{-7}$ .







**Figure S3: Aneuploidy increases the number of mutations which rescue the tumor.** Shown is the expected number of mutations, which will rescue the cancer cell population, produced through the evolutionary trajectory *sensitive*  $\rightarrow$  *mutant* (blue line, eq. (C6)) or through the trajectory *sensitive*  $\rightarrow$  *aneuploid*  $\rightarrow$  *mutant* (red line, eq. (C5)). Dashed vertical red line represents the threshold tumor size above which evolutionary rescue is likely through aneuploidy eq. (3) and the dashed vertical blue line represents the threshold tumor size above which evolutionary rescue is very likely through direct mutation eq. (2). Parameters:  $\lambda_s = 0.1$ ,  $\lambda_a = 0.0899$ ,  $\lambda_m = 0.1$ ,  $\mu_s = 0.14$ ,  $\mu_a = 0.09$ ,  $\mu_m = 0.09$ ,  $u = 10^{-2}$ ,  $v = 10^{-7}$ .




**Figure S4: Distribution of the recurrence time.** Shown is the distribution of the time for the mutant cell population to reach size  $N$ , where  $N$  is the initial number of cancer cells. The red line is analytic result eq. (F3) overlaid over the histogram of simulations. Parameters:  $N = 10^6$ ,  $\lambda_s = 0.1$ ,  $\lambda_a = 0.0899$ ,  $\lambda_m = 0.1$ ,  $\mu_s = 0.14$ ,  $\mu_a = 0.09$ ,  $\mu_m = 0.09$ ,  $u = 10^{-2}$ ,  $v = 10^{-7}$ .




**Figure S5: Standing genetic variation reduces tumor threshold size.** The probability of evolutionary rescue (i.e., the probability that the population does not go to extinction),  $p_{\text{rescue}}$ , as a function of the initial tumor size,  $N$ . Dashed vertical line shows the threshold tumor size, above which the probability is high. Blue dashed line represents the probability of evolutionary rescue as a function of  $N$  without aneuploidy ( $u = 0$ ). The black line represents the scenario where a fraction  $f = 0\%$  of the initial tumor is aneuploid, the red line represents the scenario with  $f = 5\%$  and the green line represents the scenario with  $f = 50\%$ . The dots represent simulation results and the error bars represent 95% confidence intervals ( $p \pm 1.96\sqrt{p(1-p)/n}$  where  $p$  is the fraction of simulations in which the tumor has adapted to the stress and  $n = 100$  is the number of simulations). Parameters:  $\lambda_s = 0.1, \lambda_a = 0.0899, \lambda_m = 0.1, \mu_s = 0.14, \mu_a = 0.09, \mu_m = 0.09, u = 10^{-2}, v = 10^{-7}$ .




**Figure S6:** The mean time for appearance of a resistance mutation that leads to evolutionary rescue with aneuploidy ( $u > 0$ ). Solid lines show our approximations (green: eq. (C8), blue: eq. (C9), black: eq. (C7)) compared to red markers that show mean of simulations results (with error bars for 95% confidence intervals obtained with bootstrap, see Appendix G). Blue dashed line,  $N_a^*$ . Green dashed line,  $N_m^*$ . Parameters:  $\lambda_s = 0.1$ ,  $\lambda_m = 0.0899$ ,  $\lambda_a = 0.1$ ,  $\mu_s = 0.14$ ,  $\mu_a = 0.09$ ,  $\mu_m = 0.09$ ,  $u = 10^{-2}$ ,  $\nu = 10^{-7}$ .




**Figure S7:** The mean time for the mutant cell population to reach size  $N$ , where  $N$  is the initial number of cancer cells. Solid lines show our approximations (green: eq. (D4), blue: eq. (D1) with eq. (C9) for  $\tau_a$ ; black: eq. (D1) with eq. (C7) for  $\tau_a$ ) compared to red markers that show mean of simulations results (with error bars for 95% confidence intervals obtained with bootstrap, see Appendix G). Blue dashed line,  $N_a^*$ . Green dashed line,  $N_m^*$ . Parameters:  $\lambda_s = 0.1, \lambda_a = 0.0899, \lambda_m = 0.1, \mu_s = 0.14, \mu_a = 0.09, \mu_m = 0.09, u = 10^{-2}, v = 10^{-7}$ .



**Figure S8:** The mean time for the mutant cell population to reach size  $M$ , where  $M$  is the tumor detection size. Solid lines show our approximations (green: eq. (D6) for  $N > N_m^*$ , blue: eq. (D5) with  $\tau_a$  from eq. (7) for  $N < N_a^*$ ; black: eq. (D5) with  $\tau_a$  from eq. (C7)) compared to red markers that show mean of simulations results (with error bars for 95% confidence intervals obtained with bootstrap, see Appendix G). Blue dashed line,  $N_a^*$ . Green dashed line,  $N_m^*$ . Parameters:  $\lambda_s = 0.1$ ,  $\lambda_a = 0.0899$ ,  $\lambda_m = 0.1$ ,  $\mu_s = 0.14$ ,  $\mu_a = 0.09$ ,  $\mu_m = 0.09$ ,  $u = 10^{-2}$ ,  $v = 10^{-7}$ ,  $M = 10^7$ .



**Figure S9:** The mean time for appearance of a resistance mutation that leads to evolutionary rescue with aneuploidy ( $u > 0$ ) when a fraction  $f$  of cancer cells are aneuploid at the start of drug treatment. Lines show our approximations (solid green: eq. (7) for  $N > N_m^*$ ; solid blue: eq. (7) for  $N < N_a^*$ ; solid black: eq. (C7); dashed black: eq. (C10)) compared to red markers that show mean of simulations results (with error bars for 95% confidence intervals obtained with bootstrap, see Appendix G). Blue dashed line,  $N_a^*$ . Green dashed line,  $N_m^*$ . Parameters:  $\lambda_s = 0.1, \lambda_a = 0.0899, \lambda_m = 0.1, \mu_s = 0.14, \mu_a = 0.09, \mu_m = 0.09, u = 10^{-2}, v = 10^{-7}, f = 0.14\%$ .



**Figure S10:** The probability of evolutionary rescue (i.e., the probability that the population does not become extinct),  $p_{\text{rescue}}$ , as a function of the initial tumor size,  $N$  (eq. (1)). Dashed vertical line shows the threshold tumor size,  $N_a^*$ , above which the probability is high (eq. (H3)). Red dashed line:  $v_a = 10^{-7}$ . blue line:  $v_a = 10^{-6}$ . Green line:  $v_a = 10^{-5}$ . Dots for simulations and the error bars for 95% confidence interval ( $p \pm 1.96\sqrt{p(1-p)/n}$  where  $p$  is the fraction of simulations in which the tumor has been rescued and  $n = 100$  is the number of simulations). Parameters:  $\lambda_s = 0.1, \lambda_m = 0.1, \mu_s = 0.14, \mu_a = 0.09, \mu_m = 0.09, u = 10^{-2}, v_s = 10^{-7}$ .